US20220031187A1 - Portable Heart Motion Monitor - Google Patents
Portable Heart Motion Monitor Download PDFInfo
- Publication number
- US20220031187A1 US20220031187A1 US17/399,140 US202117399140A US2022031187A1 US 20220031187 A1 US20220031187 A1 US 20220031187A1 US 202117399140 A US202117399140 A US 202117399140A US 2022031187 A1 US2022031187 A1 US 2022031187A1
- Authority
- US
- United States
- Prior art keywords
- subject
- heart
- irregular heartbeat
- signal reflected
- electromagnetic signal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002216 heart Anatomy 0.000 title claims abstract description 130
- 230000033001 locomotion Effects 0.000 title claims description 42
- 238000000034 method Methods 0.000 claims abstract description 96
- 230000001788 irregular Effects 0.000 claims description 101
- 230000005670 electromagnetic radiation Effects 0.000 claims description 28
- 238000005259 measurement Methods 0.000 claims description 22
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 17
- 206010003662 Atrial flutter Diseases 0.000 claims description 15
- 208000003663 ventricular fibrillation Diseases 0.000 claims description 15
- 206010003119 arrhythmia Diseases 0.000 claims description 13
- 208000008131 Ventricular Flutter Diseases 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 9
- 230000000747 cardiac effect Effects 0.000 abstract description 21
- 238000003745 diagnosis Methods 0.000 abstract description 4
- 238000002565 electrocardiography Methods 0.000 description 38
- 210000000038 chest Anatomy 0.000 description 26
- 230000000694 effects Effects 0.000 description 18
- 210000002837 heart atrium Anatomy 0.000 description 16
- 238000012545 processing Methods 0.000 description 15
- 238000012544 monitoring process Methods 0.000 description 14
- 210000000115 thoracic cavity Anatomy 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 11
- 230000005540 biological transmission Effects 0.000 description 10
- 208000002173 dizziness Diseases 0.000 description 10
- 238000003860 storage Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 208000000059 Dyspnea Diseases 0.000 description 9
- 206010013975 Dyspnoeas Diseases 0.000 description 9
- 208000013220 shortness of breath Diseases 0.000 description 9
- 206010033557 Palpitations Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 210000001013 sinoatrial node Anatomy 0.000 description 8
- 206010042772 syncope Diseases 0.000 description 8
- 230000008602 contraction Effects 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 206010008479 Chest Pain Diseases 0.000 description 6
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 6
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- -1 polyethylene Polymers 0.000 description 6
- 239000003237 recreational drug Substances 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000002102 Atrial Premature Complexes Diseases 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 208000006218 bradycardia Diseases 0.000 description 5
- 230000036471 bradycardia Effects 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 230000000644 propagated effect Effects 0.000 description 5
- 230000033764 rhythmic process Effects 0.000 description 5
- 210000001562 sternum Anatomy 0.000 description 5
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 208000007888 Sinus Tachycardia Diseases 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 230000006793 arrhythmia Effects 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000004301 Sinus Arrhythmia Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000001746 atrial effect Effects 0.000 description 3
- 206010003668 atrial tachycardia Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000017972 multifocal atrial tachycardia Diseases 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000004213 regulation of atrial cardiomyocyte membrane depolarization Effects 0.000 description 3
- 210000005245 right atrium Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 2
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 206010014418 Electrolyte imbalance Diseases 0.000 description 2
- 208000010496 Heart Arrest Diseases 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 206010040639 Sick sinus syndrome Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 230000002763 arrhythmic effect Effects 0.000 description 2
- 210000001992 atrioventricular node Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 238000013153 catheter ablation Methods 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 229960000632 dexamfetamine Drugs 0.000 description 2
- 229960004597 dexfenfluramine Drugs 0.000 description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960001582 fenfluramine Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000013433 lightheadedness Diseases 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229960001344 methylphenidate Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 description 1
- NNRXCKZMQLFUPL-WBMZRJHASA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 NNRXCKZMQLFUPL-WBMZRJHASA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 229910052582 BN Inorganic materials 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- PZNSFCLAULLKQX-UHFFFAOYSA-N Boron nitride Chemical compound N#B PZNSFCLAULLKQX-UHFFFAOYSA-N 0.000 description 1
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 229910000677 High-carbon steel Inorganic materials 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- HUYWAWARQUIQLE-UHFFFAOYSA-N Isoetharine Chemical compound CC(C)NC(CC)C(O)C1=CC=C(O)C(O)=C1 HUYWAWARQUIQLE-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 229910001209 Low-carbon steel Inorganic materials 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910000954 Medium-carbon steel Inorganic materials 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 206010029458 Nodal arrhythmia Diseases 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 1
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 1
- 208000008058 Reciprocating Tachycardia Diseases 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 201000008803 Wolff-Parkinson-white syndrome Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229960004156 bepridil hydrochloride Drugs 0.000 description 1
- JXBBWYGMTNAYNM-UHFFFAOYSA-N bepridil hydrochloride Chemical compound [H+].[Cl-].C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 JXBBWYGMTNAYNM-UHFFFAOYSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 238000013194 cardioversion Methods 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960002155 chlorothiazide Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
- 229960002994 dofetilide Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- ZQTNQVWKHCQYLQ-UHFFFAOYSA-N dronedarone Chemical compound C1=CC(OCCCN(CCCC)CCCC)=CC=C1C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12 ZQTNQVWKHCQYLQ-UHFFFAOYSA-N 0.000 description 1
- 229960002084 dronedarone Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000610 enoxaparin Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- 229960004213 erythromycin lactobionate Drugs 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 229960003592 fexofenadine Drugs 0.000 description 1
- 229960000449 flecainide Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000005831 heart abnormality Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960004053 ibutilide Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960001268 isoetarine Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- 229940063699 lanoxin Drugs 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 229960003088 loratadine Drugs 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 208000012866 low blood pressure Diseases 0.000 description 1
- 229950002454 lysergide Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229960001267 nesiritide Drugs 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
- 229960004448 pentamidine Drugs 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960002797 pitavastatin Drugs 0.000 description 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
- 229960000244 procainamide Drugs 0.000 description 1
- JWHAUXFOSRPERK-UHFFFAOYSA-N propafenone Chemical compound CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 JWHAUXFOSRPERK-UHFFFAOYSA-N 0.000 description 1
- 229960000203 propafenone Drugs 0.000 description 1
- 229960000697 propantheline Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 210000003742 purkinje fiber Anatomy 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 229910010271 silicon carbide Inorganic materials 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 229960005062 tinzaparin Drugs 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229960002872 tocainide Drugs 0.000 description 1
- 229960002051 trandolapril Drugs 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 210000000591 tricuspid valve Anatomy 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/0507—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves using microwaves or terahertz waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7282—Event detection, e.g. detecting unique waveforms indicative of a medical condition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0015—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by features of the telemetry system
- A61B5/0022—Monitoring a patient using a global network, e.g. telephone networks, internet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1107—Measuring contraction of parts of the body, e.g. organ, muscle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/361—Detecting fibrillation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6813—Specially adapted to be attached to a specific body part
- A61B5/6823—Trunk, e.g., chest, back, abdomen, hip
Definitions
- the invention was made with the support of the United States government under the Small Business Technology Transfer Award 1449060 by the National Science Foundation. The government may have certain rights in the invention.
- the invention provides a method of detecting an irregular heartbeat in a subject, the method comprising: a) transmitting a wavelength of electromagnetic radiation to the heart of the subject; b) detecting an electromagnetic signal reflected off the heart of the subject; and c) determining based on the electromagnetic signal reflected off the heart of the subject whether the subject has an irregular heartbeat.
- the invention provides a method comprising: a) receiving by a computer system data associated with an electromagnetic signal reflected off a heart of a subject; b) comparing by a processor of the computer system the data associated with the electromagnetic signal reflected off the heart of the subject to a reference; c) determining based on the comparison of the data associated with the electromagnetic signal reflected off the heart of the subject to the reference whether the subject has an irregular heartbeat; and d) outputting a result of the determination.
- the invention provides a device comprising: a) an antenna configured to transmit electromagnetic radiation into a thoracic cavity of a subject; b) a receiver configured to detect an electromagnetic signal reflected off the subject's heart; and c) a processor configured to identify an irregular heartbeat in the subject based on the detected electromagnetic signal reflected off the subject's heart.
- the invention provides a device comprising: a) an antenna configured to transmit electromagnetic radiation into a thoracic cavity of a subject; b) a receiver configured to detect an electromagnetic signal reflected off the subject's heart; and c) a transmitter configured to transmit data associated with the received electromagnetic signal reflected off the subject's heart.
- the invention provides a method comprising: a) administering to a subject having an irregular heartbeat an intervention for the irregular heartbeat; b) monitoring the subject with a radar device; and c) determining based on the monitoring whether the intervention for the irregular heartbeat modulates the irregular heartbeat in the subject.
- the invention provides a method comprising: a) administering to a subject an intervention; b) monitoring the subject with a radar device; and c) determining based on the monitoring whether the intervention induces an irregular heartbeat in the subject.
- FIG. 1 depicts a representative device of the invention.
- FIG. 2 shows comparative ECGs for atrial fibrillation and a normal heartbeat.
- FIG. 3 is a representative ECG for atrial flutter.
- FIG. 4 is a representative ECG for ventricular fibrillation.
- FIG. 5 depicts a function of an example device of the invention.
- FIG. 6 illustrates the thickness of different tissues in the human body.
- FIG. 7 depicts signal loss inside human tissue.
- FIG. 8 is a block diagram illustrating a first example architecture of a computer system that can be used in connection with example embodiments of the present invention.
- FIG. 9 is a diagram illustrating a computer network that can be used in connection with example embodiments of the present invention.
- FIG. 10 is a block diagram illustrating a second example architecture of a computer system that can be used in connection with example embodiments of the present invention.
- FIG. 11 illustrates a global network that can transmit a product of the invention.
- FIG. 12 depicts a representative device of the invention.
- FIG. 13 depicts a representative device of the invention.
- FIG. 14 illustrates representative implementations of an example device of the invention.
- FIG. 15 is paired ECGs and measurements with a representative device of the invention in human subjects.
- FIG. 16 is a paired ECG and measurement with a representative device of the invention in a human subject.
- FIG. 17 is paired ECGs and measurements with a representative device of the invention in a human subject.
- FIG. 18 is a paired ECG and measurement with a representative device of the invention in a human subject.
- FIG. 19 depicts a representative device of the invention and measured waveforms from the representative radar device.
- FIG. 20 illustrates a method of monitoring that can be used in connection with example embodiments of the present invention.
- FIG. 21 depicts measured waveforms from the representative radar device.
- Portable testing devices have the potential to reduce healthcare costs and improve the delivery of healthcare to patients who do not have immediate or easy access to healthcare facilities.
- a portable heart motion monitor can rapidly and conveniently determine the cardiac status of patients without requiring travel to a hospital or doctor's office. This convenience can reduce costs by reducing frequency of hospital visits and improving diagnosis rates due to increased patient compliance.
- a compact and portable heart motion monitor provides a special benefit to patients who are elderly, incapacitated, or living in remote areas, who would otherwise have to travel tediously to receive adequate healthcare.
- the invention described herein provides a simple, cost-effective, and efficient method to obtain information about a patient's heart from anywhere that the patient goes, even in the comfort of the patient's home.
- a mobile device of the invention can be used in a subject's home without clinical intervention.
- the device described herein can detect heart motion in a subject continuously and non-invasively.
- the device can be worn by the subject, attached to the subject, mounted, stationary, or otherwise convenient for outpatient use.
- An irregular heartbeat also known as cardiac dysrhythmia or arrhythmia, is any of a group of conditions wherein the electrical activity of the heart is irregular and often faster or slower than is normal.
- An irregular heartbeat can be symptomatic of deeper underlying cardiac conditions.
- the standard diagnostic test for arrhythmias is electrocardiography (ECG).
- ECG electrocardiography
- An ECG is a recording of the electrical activity of the heart, the output of which is a series of waveforms corresponding to the electrical impulses generated by the polarization and depolarization of cardiac tissue, known as an electrocardiogram (also ECG).
- ECG electrocardiogram
- While an ECG is a powerful method to glean a variety of information about a patient's cardiac status, the test requires a significant amount of clinical expertise and a visit to the clinic or hospital. This inconvenience makes the process of obtaining an ECG unappealing, especially if the patient is elderly, incapacitated, or resides in a rural area where access to a clinic can be difficult
- Diagnosis of an irregular heartbeat can be essential in determining underlying cardiac abnormalities or disease.
- Subjects with atrial fibrillation for example, can have a higher risk of stroke due to the pooling of blood in atria, which can lead to blood clots.
- development of devices that can rapidly and easily monitor cardiac activity can lead to efficient and effective diagnoses of cardiac conditions.
- Devices that can be used remotely can increase patient compliance, thereby improving diagnosis success rates.
- a device described herein can be worn by a subject to monitor cardiac activity in various environments. Activity can be monitored in a care setting, such as a clinic, hospital, or doctor's office, or in a place away from a clinic or a hospital, for example, at home, at school, or any place where the user wishes to wear the device.
- a device described herein can also be used during everyday activity, for example, while driving a car, doing daily errands, exercising, shopping, or during periods of rest or sleep.
- the device described herein can use, for example, electromagnetic signals to determine the motion of a subject's heart to monitor and diagnose the heart for irregularities.
- a device described herein can be used during short-term visits to a clinic, hospital, or doctor's office.
- the device can also be used by a subject during an inpatient visit to a hospital, or while a subject is recovering in a hospital, but needs the freedom to be ambulatory.
- FIG. 1 illustrates a device 101 to determine the motion of the heart of a subject.
- the transmitter 102 of the transceiver circuit 109 generates a signal that is routed to an antenna 105 via the duplexer 104 .
- the signal can then propagate 108 from the antenna to an object of interest 106 , such as a heart of portion thereof.
- the signal can be, for example, pulsed or continuous.
- the signal is electromagnetic radiation such as a radio wave, an electromagnetic signal, a wavelength or frequency of the electromagnetic spectrum, a wavelength of light, or a photon.
- the signal After transmission of the signal, the signal can be reflected 107 off the object of interest 106 , such as the heart.
- the device comprises a radar system.
- Non-limiting examples of the types of radar that can be used in the device include ultrawide bandwidth radar, continuous wave Doppler radar, pulsed Doppler radar, frequency-modulated continuous wave radar, or pseudorandom code modulated continuous wave radar.
- FIG. 12 illustrates an embodiment of a device to determine the motion of the heart of a subject.
- the pulse generator 1201 generates a pulse 1202 that is routed through a pulsed sine wave generator 1203 to generate a pulse waveform 1204 .
- the pulse waveform 1204 is then routed to the antenna 1206 via the duplexer 1205 .
- the pulse waveform 1204 can then propagate from the antenna 1206 to a target 1207 , such as a heart of portion thereof.
- the pulse waveform 1204 is electromagnetic radiation such as a radio wave, an electromagnetic signal, a wavelength or frequency of the electromagnetic spectrum, a wavelength of light, or a photon.
- the pulse waveform 1204 can be reflected off the target 1207 , such as the heart.
- the pulse waveform 1204 is detected by the antenna 1206 and routed to the mixer 1209 via the duplexer 1205 , which converts the detected pulse waveform into a duplexed waveform 1208 .
- the duplexed waveform 1208 is propagated from the mixer 1209 to the amplifier and filters 1210 to generate the filtered waveform 1211 .
- the filtered waveform 1211 is then propagated to the signal processing and display unit 1212 .
- the device comprises a radar system.
- Non-limiting examples of the types of radar that can be used in the device include ultrawide bandwidth radar, continuous wave Doppler radar, pulsed Doppler radar, frequency-modulated continuous wave radar, and pseudorandom code modulated continuous wave radar.
- multiple radar sensors can be used to increase the accuracy of the cardiac measurements.
- Multiple radar sensors also measure heart motion profiles from different positions of view and generate a multi-dimensional data set that can be inverted to solve for the motion of the heart in two dimensions. This method can provide accurate measurements by reducing the effect of random movement or misalignment of individual radar sensors.
- FIG. 13 illustrates an embodiment of a device to determine the motion of the heart of a subject.
- a voltage controlled oscillator 1302 generates a waveform.
- the waveform is then propagated through a splitter 1303 and a first amplifier 1304 to the circulator 1305 .
- the waveform is then carried from a circulator 1305 to an antenna 1306 .
- a reflected waveform is then carried from the antenna 1306 to the circulator 1305 .
- the waveform is then propagated to a second amplifier 1307 .
- the waveform is then filtered through a bandpass filter 1308 .
- the filtered waveform is then decoded using a quadrature demodulation chip 1309 .
- the decoded waveform is then transmitted to a signal acquisition unit 1310 .
- the device comprises a radar system.
- Non-limiting examples of the types of radar that can be used in the device include ultrawide bandwidth radar, continuous wave Doppler radar, pulsed Doppler radar, frequency-modulated continuous wave radar, and pseudorandom code modulated continuous wave radar.
- a device described herein comprises a monostatic radar architecture, wherein only one antenna is used for both transmission and reception.
- a device described herein comprises a duplexer, which can separate transmitted and received signals when one antenna is used for both transmission and reception. In a monostatic radar system, signals generated are passed directly to the antenna, while received signals from the antenna are routed to the receiver portion.
- a duplexer can provide isolation between the transmit and receive paths, allowing for one antenna to perform both functions.
- a device described herein comprises a bistatic radar architecture.
- a device comprising a bistatic radar architecture two antennas are spatially separated for the transmit and receive paths.
- Non-limiting examples of antennae that can be used in the device include an isotropic radiator, a dipole antenna, a Yagi-Uda antenna, a random wire antenna, a horn antenna, a parabolic antenna, and a patch antenna.
- the antenna can be detachable or removable from the device.
- the antenna can be interchangeable or exchangeable for a different antenna, for example, an antenna of a differing strength.
- the antenna can be placed, for example, inside, outside, in proximity to, adjacent to, on top of, or below the device.
- the device can determine if the subject has a condition associated with an irregular heartbeat.
- conditions associated with an irregular heartbeat include paroxysmal atrial fibrillation, paroxysmal atrial flutter, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter, supraventricular tachycardia, Wolff-Parkinson-White syndrome, premature ventricular contraction, premature atrial contraction, sick sinus syndrome, sinus arrhythmia, sinus tachycardia, multifocal atrial tachycardia, or bradycardia.
- a device can comprise a computer system that can receive data associated with a signal reflecting off the subject's heart. The data that is received by the computer system can then be compared by a processor of the computer system to a reference to determine if the subject has an irregular heartbeat.
- references that can be used by the computer system include past measurements from the subject, measurements from a healthy subject, statistical averages of the symptom being measured, and reference texts.
- the computer system can then output a result of the determination.
- the processor is located in a housing common to the source of the signal in the device. In some embodiments, the processor is not located in a housing common to the source of the signal in the device.
- the device comprises a processor coupled to a transmitter configured to transmit data from the device to a remote location, for example, a hospital, a clinic, or a doctor's office.
- the transmitter can be configured to transmit data wirelessly, for example, via Bluetooth, wireless networks, cell phone networks, a cloud network, or the internet.
- the device can use Bluetooth to connect to an analysis device, including but not limited to, a cell phone or computer system.
- the transmission is wired.
- the processor can be configured to transmit data to a plurality of receivers in a plurality of geographic locations.
- the processor can transmit data over a distance of about 1 mile, about 2 miles, about 3 miles, about 4 miles, about 5 miles, about 6 miles, about 7 miles, about 8 miles, about 9 miles, or about 10 miles. In some embodiments, the processor can transmit data over a distance of at least 10 miles. In some embodiments, the processor can transmit data over a distance of at least 50 miles. In some embodiments, the device comprises a Global Positioning System (GPS).
- GPS Global Positioning System
- a device described herein can be, or cannot be, worn by a subject.
- the device can be attached to a subject's body using, for example, a chest strap, a chest vest, an arm band, a wrist band, a headband, a belt, an adhesive tape, or glue.
- a device described herein can be embedded in a subject's clothing, for example, an undergarment, a bra, a shirt, a jacket, or a sweater.
- a device described herein can be embedded in, for example, a watch, an earring, a necklace, a ring, or a bracelet. The device can also be unattached from the subject's body.
- a device described herein can be attached to, for example, a wall, a headboard, a bed, a mirror, a nightstand, a chair, or other furniture in proximity to the subject.
- the device can be embedded in, for example, a mattress, a pillow, a comforter, or a sofa.
- a device described herein can be, or cannot be, at a distance from a subject.
- the distance between the device and the subject can be zero, at least about 1 centimeter (cm), at least about 2 cm, at least about 3 cm, at least about 4 cm, at least about 5 cm, at least about 6 cm, at least about 7 cm, at least about 8 cm, at least about 9 cm, at least about 10 cm, at least about 11 cm, at least about 12 cm, at least about 13 cm, at least about 14 cm, at least about 15 cm, at least about 16 cm, at least about 17 cm, at least about 18 cm, at least about 19 cm, at least about 20 cm, at least about 21 cm, at least about 22 cm, at least about 23 cm, at least about 24 cm, at least about 25 cm, at least about 26 cm, at least about 27 cm, at least about 28 cm, at least about 29 cm, at least about 30 cm, at least about 31, at least about 32 cm, at least about 33 cm, at least about 34 cm, at least about 35 cm, at least about 36 cm,
- the distance between the device and the subject can be at most about 1 centimeter (cm), at most about 2 cm, at most about 3 cm, at most about 4 cm, at most about 5 cm, at most about 6 cm, at most about 7 cm, at most about 8 cm, at most about 9 cm, at most about 10 cm, at most about 11 cm, at most about 12 cm, at most about 13 cm, at most about 14 cm, at most about 15 cm, at most about 16 cm, at most about 17 cm, at most about 18 cm, at most about 19 cm, at most about 20 cm, at most about 21 cm, at most about 22 cm, at most about 23 cm, at most about 24 cm, at most about 25 cm, at most about 26 cm, at most about 27 cm, at most about 28 cm, at most about 29 cm, at most about 30 cm, at most about 31, at most about 32 cm, at most about 33 cm, at most about 34 cm, at most about 35 cm, at most about 36 cm, at most about 37 cm, at most about 38 cm, at most about 39 cm, at most about 40 cm, at
- a device described herein can be, or cannot be, in contact with a subject's skin.
- the device can be placed in proximity to, for example, the chest, the sternum, the heart, or the thoracic cavity of a subject.
- the device can be placed directly on, for example, the chest, the sternum, or the thoracic cavity of a subject.
- the device can be placed in the center of the chest, the upper part of the chest, the lower part of the chest, the left part of the center of the chest, or the right part of the center of the chest of a subject.
- the device can be placed on the back of a subject, for example, in line with, above, below, left, or right of the sternum.
- the device can be placed in front of, for example, the chest, the sternum, or the thoracic cavity of a subject.
- a device described herein can be used by a subject holding breath. In some embodiments, the device can be used by a subject breathing normally.
- a device described herein can be used by a subject hourly, daily, weekly, monthly, yearly, occasionally, frequently, continuously, or chronically.
- a device described herein can be used by a subject as needed based on a condition of the subject, upon a doctor's recommendation, as desired by the subject, as required to monitor the condition of the subject properly, or for diagnostic or research purposes.
- a device of the invention has an average output power of about 1 ⁇ W, about 2 ⁇ W, about 3 ⁇ W, about 4 ⁇ W, about 5 ⁇ W, about 6 ⁇ W, about 7 ⁇ W, about 8 ⁇ W, about 9 ⁇ W, about 10 ⁇ W, about 20 ⁇ W, about 30 ⁇ W, about 40 ⁇ W, about 50 ⁇ W, about 60 ⁇ W, about 70 ⁇ w, about 80 ⁇ W, about 90 ⁇ W, about 100 ⁇ W, about 200 ⁇ W, about 300 ⁇ W, about 400 ⁇ w, about 500 ⁇ W, about 600 ⁇ W, about 700 ⁇ W, about 800 ⁇ W, about 900 ⁇ W, about 1 mW, about 2 mW, about 3 mW, about 4 mW, about 5 mW, about 6 mW, about 7 mW, about 8 mW, about 9 mW, about 10 mW, about 15 mW, about 20 mW, about 25 .
- a device described herein can produce pulses of electromagnetic waves.
- the duration of the pulses can be about 1 ps, about 2 ps, about 3 ps, about 4 ps, about 5 ps, about 6 ps, about 7 ps, about 8 ps, about 9 ps, about 10 ps, about 20 ps, about 30 ps, about 40 ps, about 50 ps, about 60 ps, about 70 ps, about 80 ps, about 90 ps, about 100 ps, about 110 ps, about 120 ps, about 130 ps, about 140 ps, about 150 ps, about 160 ps, about 170 ps, about 180 ps, about 190 ps, about 200 ps, about 250 ps, about 300 ps, about 350 ps, about 400 ps, about 450 ps, about 500 ps, about 600 ps, about 700 ps, about 800 ps,
- the repetition rate of the pulses can be about 0.1 MHz, about 0.2 MHz, about 0.3 MHz, about 0.4 MHz, about 0.5 MHz, about 0.6 MHz, about 0.7 MHz, about 0.8 MHz, about 0.9 MHz, about 1 MHz, about 2 MHz, about 3 MHz, about 4 MHz, about 5 MHz, about 6 MHz, about 7 MHz, about 8 MHz, about 9 MHz, about 10 MHz, about 15 MHz, about 20 MHz, about 25 MHz, about 30 MHz, about 35 MHz, about 40 MHz, about 45 MHz, about 50 MHz, about 60 MHz, about 70 MHz, about 80 MHz, about 90 MHz, or about 100 MHz.
- Non-limiting examples of device shape include a cube, a sphere, a cylinder, a square, a rectangle, and a circle.
- a device described herein can have a height (H), width (W), and depth (D), each independently of about 0.05 inches, about 0.1 inches, about 0.15 inches, about 0.2 inches, about 0.25 inches, about 0.3 inches, about 0.35 inches, about 0.4 inches, about 0.45 inches, about 0.5 inches, about 0.6 inches, about 0.7 inches, about 0.8 inches, about 0.9 inches, or about 1 inch.
- the device is a cube.
- the device can have dimensions of about 1 inch height by about 1 inch width by about 0.2 inches depth.
- Non-limiting examples of materials that can be used in the manufacture of the device include polyvinyl chloride, polyethylene, polypropylene, polystyrene, polyurethane, polyethylene terephthalate, polycarbonate, silicone, and combinations thereof. Further non-limiting examples of materials that can be used in the manufacture of the device include steel, low-carbon steel, medium-carbon steel, high-carbon steel, aluminum, brass, copper, lead, magnesium, nickel, titanium, zinc, and combinations thereof. Additional non-limiting examples of materials that can be used in the manufacture of the device include copper wire, aluminum wire XHHW wire, THWN wire, and THHN wire.
- Non-limiting examples of chips that can be used in the manufacture of the device include dynamic random access memory chips, microprocessors, application specific integrated circuits, digital signal processors, programmable memory chips, and combinations thereof.
- Non-limiting examples of semiconductors that can be used in the manufacture of the device include diamond, silicon, germanium, tin, silicon carbide, selenium, tellurium, boron nitride, zinc oxide, copper (I) oxide, and combinations thereof.
- the device has a total mass of less than about 100 grams.
- the total mass of the device can be about 1 gram, about 2 grams, about 3 grams, about 4 grams, about 5 grams, about 6 grams, about 7 grams, about 8 grams, about 9 grams, about 10 grams, about 15 grams, about 20 grams, about 25 grams, about 30 grams, about 35 grams, about 40 grams, about 45 grams, about 50 grams, about 60 grams, about 70 grams, about 80 grams, about 90 grams, about 100 grams, about 110 grams, about 120 grams, about 130 grams, about 140 grams, about 150 grams, about 200 grams, about 250 grams, about 300 grams, about 350 grams, about 400 grams, about 450 grams, about 500 grams, about 550 grams, about 600 grams, about 650 grams, about 700 grams, about 750 grams, about 800 grams, about 850 grams, about 900 grams, about 950 grams, or about 1000 grams.
- Any tool, interface, engine, application, program, service, command, or other executable item can be provided as a module encoded on a computer-readable medium in computer executable code.
- the invention provides a computer-readable medium encoded therein computer-executable code that encodes a method for performing any action described herein, wherein the method comprises providing a system comprising any number of modules described herein, each module performing any function described herein to provide a result, such as an output, to a user.
- the device described herein can be used to monitor the cardiac activity of a subject, and detect abnormalities.
- the monitoring can detect the motion of the subject's heart.
- the device can also detect, for example, the relative position of a portion of the heart as compared to the rest of the heart, a movement of the left atrium, a movement of the right atrium, a movement of the left ventricle, a movement of the right ventricle, a change in a dimension of the heart, the heart rate, the pattern of the heart rate, the regularity of the heartbeat, the irregularity of the heartbeat, the strength of the heartbeat, the intensity of the heartbeat, the position of the heart muscles, the velocity of the heart muscles, the relative strength of diastole, the relative strength of systole, the sinus rhythm of the atria, the sinus rhythm of the ventricles, ejection fraction, cardiac output, and stroke volume.
- the device described herein can obtain and record measurements, for example, when the subject is at rest, in motion, doing light exercise, doing heavy exercise, walking, running, jogging, biking, or sleeping. Measurements taken during these times can be compared to readings taken during other times to determine the cardiac activity of the subject.
- a subject can be, for example, an elderly adult, an adult, an adolescent, a child, a toddler, or an infant.
- a subject can be, for example, an individual with a heart condition or an individual without a heart condition.
- a subject can be a patient.
- An irregular heartbeat also known as cardiac dysrhythmia or arrhythmia, is characterized by an abnormal heart rate or rhythm, and a change in the electrical activity of the heart.
- An irregular heartbeat can be caused by, for example, coronary artery disease, electrolyte imbalances, scarring of the heart muscle from a previous heart attack, cardiomyopathy, hypertension, diabetes, hyperthyroidism, stress, smoking, medication side effects (for example, chemotherapy-induced cardiotoxicity), excessive consumption of alcohol, excessive consumption of caffeine, or drug abuse.
- the major symptoms of an irregular heartbeat include, for example, a fluttering sensation in the chest, palpitations, chest pain, shortness of breath, slow heartbeat, shortness of breath, dizziness, and syncope.
- Atrial fibrillation is a common condition associated with an irregular heartbeat, with almost half a million cases diagnosed in the United States annually.
- the normal electrical impulses produced by the sinus node of the heart for a regular heartbeat are overwhelmed by rapid electrical discharges produced in the atria and adjacent parts of the pulmonary veins.
- These rapid and irregular abnormal discharges can exceed 350 discharges per minute, cause ineffective contractions of the atria, and reduce the ability of the atria to pump blood into the ventricles.
- These complications further lead to irregular ventricular contractions, causing a discrepancy in the rate of contractions in the atria and ventricles.
- FIG. 2 shows an ECG for a subject with a normal heart rate and one for a subject with atrial fibrillation.
- the arrow in the bottom ECG denotes a P wave found in subjects with a normal heartbeat.
- the P wave on an ECG represents the depolarization that spreads through the sinoatrial node to the atria, also known as atrial depolarization.
- Atrial depolarization is the first step of the cardiac cycle and occurs when there is an influx of Ca′ ions, which leads to contractions within the atrium.
- a patient with atrial fibrillation will not have a P wave on an ECG due to the lack of atrial depolarization.
- Atrial fibrillation In the place of the P wave, small spikes in electrical activity provide evidence of electrical disturbance, as denoted by the arrow in the top ECG.
- the major symptoms of atrial fibrillation can include palpitations, chest pain, shortness of breath, and syncope.
- the heart rate can exceed about 100 beats per minute. Paroxysmal atrial fibrillation can be an episode of atrial fibrillation that occurs and then stops and does not happen persistently or consistently.
- Atrial flutter is an abnormal heart rhythm that occurs within the atria. Atrial flutter can be caused by a rapid electrical impulse that begins, most commonly, in the right atrium which moves in a localized self-perpetuating loop. The circuit can go around the atria at about 300 beats per minute, in turn causing the ventricles to beat very rapidly. The self-perpetuating loop circles the right atrium and passes through the cavo-tricuspid isthmus, an area of fibrous tissue in the lower atrium between the inferior vena cava and the tricuspid valve. A characteristic ECG of a patient with atrial flutter is shown in FIG. 3 . The rapid, but regular, beating of the atria can lead to a saw tooth pattern on an ECG.
- the major symptoms of atrial flutter can include palpitations, shortness of breath, rapid heart rate, chest pain, lightheadedness, fatigue, and low blood pressure. Paroxysmal atrial flutter can be an episode of atrial flutter that occurs and then stops and does not happen persistently or consistently.
- Ventricular flutter can be characterized by a rapid heartbeat that originates in the ventricles. Ventricular flutter generally progresses to ventricular fibrillation and is short-lived. Ventricular fibrillation can occur by an uncoordinated contraction in the ventricles, causing a quiver rather than proper contractions. The heartbeat can exceed 350 beats per minute. This improper contraction of the ventricles most often leads to cardiac arrest due to an inability of the ventricles to pump blood through the heart. The most common cause of ventricular fibrillation is coronary artery disease. The most immediate symptoms of ventricular fibrillation are sudden collapse or loss of consciousness, and fainting. Early signs of ventricular fibrillation can include dizziness, nausea, chest pain, rapid heart rate, or palpitations. Generally, if a subject is not treated within five minutes of collapse due to ventricular fibrillation, the subject will undergo cardiac arrest. The erratic heartbeats present during ventricular fibrillation can be seen in the ECG in FIG. 4 .
- SVT Supraventricular tachycardia
- SVT is a rapid heart rate that originates in or above the atrioventricular node. Episodes of SVT can last for a few seconds, minutes, hours, or days. The major symptoms of SVT include a pounding heart, shortness of breath, rapid heartbeat, dizziness, chest pain, and syncope.
- WPW syndrome is caused by the presence of an abnormal accessory electrical conduction pathway between the atria and the ventricles. Electrical signals travelling down this abnormal pathway can stimulate the ventricles to contract prematurely, resulting in a unique type of supraventricular tachycardia, referred to as an atrioventricular reciprocating tachycardia. Often, WPW syndrome is asymptomatic, but symptoms can include palpitations, shortness of breath, dizziness, and syncope.
- PVC Premature ventricular contraction
- PVC is a relatively common event and is generally considered benign, but can indicate hypoxia in the myocardium. PVC most commonly occurs in the elderly and in men, and is generally asymptomatic and difficult to detect without an ECG. Possible signs of a PVC event include palpitations, shortness of breath, dizziness, increased awareness of one's heartbeat, and a feeling of forceful beats.
- PACs Premature atrial contractions
- Sick sinus syndrome includes arrhythmias that originate in the sinus node. SSS is often associated with coronary artery disease and valvular lesions. SSS is most common in the elderly and in children who have undergone cardiac surgery in the atria. Symptoms of SSS include syncope, dizziness, shortness of breath, chest pain, fatigue, headache, and nausea.
- Sinus arrhythmia refers to the natural variation in heartbeat that occurs with breathing. A mild slowing and acceleration of heart rate occurs with breathing. Sinus arrhythmia is most pronounced in children and steadily decreases with age.
- Sinus tachycardia is a rapid heart rhythm originating in the sinoatrial node with a heartbeat that can exceed 100 beats per minute. Sinus tachycardia is generally a response to normal physiological situations such an exercise and stress. The main symptom of sinus tachycardia is an increased heart rate.
- Multifocal atrial tachycardia is a cardiac arrhythmia associated with chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- Multifocal atrial tachycardia occurs when groups of cells outside of the sinoatrial node begin to control the heartbeat, and the heart rate exceeds 100 beats per minute. Symptoms can include tightness in the chest, light-headedness, syncope, palpitations, shortness of breath, and dizziness.
- Bradycardia is a resting heart rate of less than 60 beats per minute, generally remaining asymptomatic until the rate drops below 50 beats per minute. Symptoms of bradycardia include fatigue, weakness, dizziness, and syncope. Bradycardia can be caused by recreational drug use, metabolic or hormonal imbalances, electrolyte imbalances, coronary artery disease, vascular heart disease, or valvular heart disease. Generally, bradycardia can be caused by problems that arise in the sinoatrial node or atrioventricular node.
- a device described herein can be used to determine, observe, record, time, track, or calculate, the burden, or duration, of an irregular heartbeat in a subject.
- the device can record measurements for a specified period of time to determine the percentage of time the subject has an irregular heartbeat.
- the device can record measurements for about one minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about one hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 10 hours, about 20 hours, about one day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about one week, about 2 weeks, about 3 weeks, about one month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about one year, about 2 years, or about 3 years.
- the burden can be determined over any time period by an analysis of the data, comparing episodes of irregular heartbeat to the subject's own ordinary heartbeat or to a reference heartbeat.
- the device described herein can be used to monitor cardiac activity in a subject undergoing an intervention for an irregular heartbeat.
- the intervention can involve pharmacological agents, devices that are, or are not, implanted in the subject to modulate the heartbeat, surgery, and combinations thereof.
- the device can be used to determine if the intervention is modulating the irregular heartbeat by comparing readings taken before and after administration of the intervention, or during the course of therapy.
- Non-limiting examples of interventions used by a subject that can be monitored by the present invention include amiodarone, bepridil hydrochloride, disopyramide, dofetilide, dronedarone, flecainide, ibutilide, lidocaine, procainamide, propafenone, propranolol, quinidine, sotalol, tocainide, amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, verapamil, acebutolol, atenolol, betaxolol, bisoprolol, hydrochlorothiazide, carteolol, esmolol, metoprolol, nadolol, penbutolol, pindolol, timolol, warfarin, dalterparin, enoxapar
- the device described herein can be used to monitor cardiac activity in a subject undergoing an intervention for a non-irregular heartbeat condition.
- the intervention can comprise pharmacological agents, surgery, and combinations thereof.
- the device can be used to determine whether the intervention is inducing an irregular heartbeat by comparing readings taken before and after administration of the intervention, or during the course of therapy.
- Non-limiting examples of interventions used by a subject that can be monitored by the present invention include diphenhydramine, chlorpheniramine, clemastine, brompheniramine, hydroxyzine, cetirizine, fexofenadine, loratadine, dextroamphetamine, methamphetamine, methylphenidate, fenfluramine, dexfenfluramine, MDMA, cocaine, pseudoephedrine, albuterol, isoproterenol, salmeterol, isoetharine, phencyclidine, tranylcypromine, phenelzine, aminophylline, caffeine, nortriptyline, amitriptyline, imipramine, desipramine, scopolamine, propantheline, atropine, cisapride, erythromycin lactobionate, pentamidine, chloroquine, amantadine, and combinations thereof.
- the device described herein can be used to monitor cardiac activity in a subject undergoing an intervention for a cancer, tumor, hyperproliferative disorder, or neoplasia.
- the intervention can comprise pharmacological agents, surgery, and combinations thereof.
- the device can be used to determine whether the intervention is inducing an irregular heartbeat by comparing readings taken before and after administration of the intervention, or during the course of therapy.
- Non-limiting examples of interventions used by a subject that can be monitored by the present invention include doxorubicin, adriamycin, capecitabine, gemcitabine, cytarabine, paclitaxel, docetaxel, cisplatin, carboplatin, oxaliplatin, 5-fluorouracil, chlorambucil, cyclophosphamide, busulfan, melphalan, arsenic trioxide, IL-2, methotrexate, trastuzumab, sunitinib, cetuximab, alemtuzumab, rituximab, thalidomide, amsacrine, dispeptide, and combinations thereof.
- the device described herein can be used to monitor cardiac activity in a subject using recreational drugs.
- the device can be used to determine whether the recreational drug use is inducing an irregular heartbeat by comparing readings taken in the presence and absence of recreational drug use, or during the course of recreational drug use.
- Non-limiting examples of recreational drugs used by a subject that can be monitored by the present invention include dextroamphetamine, methamphetamine, methylphenidate, fenfluramine, dexfenfluramine, MDMA, cocaine, phencyclidine, lysergic acid diethylamide, psilocybin, morphine, heroin, volatile inhalants, cannabis and combinations thereof.
- a detection system of the invention can comprise a transmitter, a receiver, and an antenna.
- the transmitter can generate a signal that is radiated into a space containing an object of interest by the antenna.
- the signal can then be reflected off the object of interest, and a reflected signal can be detected by the receiver.
- the receiver can amplify the signal for conversion to, for example, visual or audio data.
- Ultrasound involves the use of high frequency sound waves outside the range of human hearing to create images of, for example, organs and systems within the human body.
- Medical sonography is the practice of imaging organs within the body.
- Ultrasound images (sonograms) are made by sending a pulse of ultrasound into tissue using an ultrasound transducer. The sound reflects and echoes off parts of the tissue and this echo is recorded and displayed as an image to the operator.
- the electromagnetic (EM) spectrum is a continuum of all the possible frequencies of electromagnetic radiation. Electromagnetic radiation can be described by physical properties including frequency, wavelength, and energy. The different regions of the EM spectrum, in decreasing order of wavelength and increasing order of frequency, include radio waves, microwaves, far infrared, near infrared, visible, ultraviolet, X-rays, gamma rays, and high-energy gamma rays.
- Radio waves are generally propagated via the use of an antenna and can have wavelengths that range from hundreds of kilometers to a millimeter. Radio waves can be used for communication satellites, navigation systems, radio communication, broadcasting, and radar.
- Microwaves have wavelengths that range from one meter to millimeters. Microwaves are used in spacecraft communication and radar technology. Some television and telephone communications are transmitted long distances by microwaves between ground stations and communications satellites. Microwaves can be absorbed by molecules that have dipole moments in liquids.
- Infrared radiation is characterized by wavelengths that range from about a millimeter to several hundred nanometers. Infrared energy is emitted or absorbed by molecules when changing rotational-vibrational movements. Infrared energy elicits vibrational modes in a molecule through a change in the dipole moment, making infrared a useful frequency range for study of these energy states for molecules. Most thermal energy emitted from objects at room temperature is infrared.
- the visible region of the EM spectrum is the portion of the spectrum to which the human eye is most sensitive. Electromagnetic radiation with wavelengths of between 380 and 760 nanometers is detectable by the human eye and perceived as visible light.
- UV radiation typically has wavelengths between 100 and 400 nanometers. UV light can be found in sunlight and has the potential to damage biological molecules due to its ability to alter chemical bonds. UV rays having very short wavelengths can ionize molecules.
- X-rays have wavelengths in the range of about one to tenths of a nanometer. X-rays have the ability to penetrate through relatively thick objects without much scattering or absorption, thus making them useful for imaging visually opaque objects and are widely used in medical radiography and airport security scanners.
- Gamma rays have extremely short wavelengths and a very high frequency. Natural sources of gamma rays include decay from naturally occurring radioisotopes. Gamma rays are also found in space as a result of supernova explosions. Due to their high energy, gamma rays are highly penetrating and can diffuse throughout the human body and cause radiation sickness.
- Radar radio detection and ranging
- Radio waves are a portion of the electromagnetic spectrum and are characterized by low frequency and long wavelengths.
- a radar system can use radio waves as a mechanism for the detection of objects.
- Ultra-wideband (UWB) radar systems can use radio waves to transmit information spread over large bandwidths, for example, greater than 500 MHz.
- UWB radar systems can accomplish this task via pulse-modulation of the signal, in that UWB transmissions transmit information by generating radio waves at specific time intervals over a large bandwidth.
- Non-UWB transmissions can employ continuous signaling in which only the frequency, power level, or phase of the wave, but not the time interval, is changed.
- Doppler radar utilizes the Doppler effect to produce velocity data about objects at a distance.
- Doppler radar can beam a microwave signal toward a desired target and listen for a reflection. This process allows for analysis of how the object's motion alters the frequency of the returned signal motion, and provides data about the object's velocity.
- Continuous wave Doppler radar transmits a continuous wave of radio energy, allowing for the determination of an object's velocity without providing any range or distance data.
- Frequency-modulated continuous wave (FMCW) Doppler radar differs from continuous wave Doppler radar in that the frequency of the transmitted signal can be varied, allowing for measurements of an object's distance.
- Use of pseudorandom code modulated continuous wave radar can provide further refinement as to an object's distance and range. This refinement occurs via modulation of the transmitter's codes to meet frequency and range requirements for the objects of interest.
- Pulsed Doppler radar uses pulse-timing techniques and the Doppler effect to determine the distance of an object.
- Pulsed Doppler systems differ from continuous wave systems by sending short pulses of radio energy rather than a continuous transmission of radio energy to an object.
- the range of an object is determined by the measuring the elapsed time between pulses sent to and reflected off the object.
- FIG. 5 depicts an example device of the present invention.
- the device 502 can comprise an antenna 503 and be positioned in proximity to, for example, a human heart 501 .
- the antenna can transmit 506 a signal 504 to the heart.
- the signal 504 can reflect off, for example, the muscle tissue of the heart.
- the reflected signal 505 can then be received 507 by the device 502 and processed for analysis.
- FIG. 6 illustrates the tissue thickness, in inches, of skin, fat, muscle, and bone anterior to the heart of a human. The amount of muscle tissue is relatively low. When radar signals were radiated through various tissues including skin, fat, muscle, and bone, the greatest loss of radar signal occurred in the muscle tissue, as demonstrated in FIG. 7 .
- the loss of signal intensity was correlated positively with the frequency of the signal, as shown in FIG. 7 .
- the frequency (GHz) of the signal was increased, the total loss of signal (dB) was most significant in the muscle, while other tissues only accounted for a minor portion of signal loss.
- dB total loss of signal
- a three-dimensional full-wave simulation was employed.
- a three-dimensional model of the heart, or chest cavity was used.
- the complexity of the model was reduced by removing portions of the chest cavity that do not move, and thus are not relevant for modeling the motion of the heart.
- the heart model was imported into a wave simulation program to determine the signal received at the antenna in the form of a magnetic or electric field distribution.
- the extracted waveforms were fed into a circuit simulator to determine the correlation between the output signal and the motion of the heart.
- FIG. 8 is a block diagram illustrating a first example architecture of a computer system 800 that can be used in connection with example embodiments of the present invention.
- the example computer system can include a processor 802 for processing instructions.
- Non-limiting examples of processors include: Intel Core i7TM processor, Intel Core i5TM processor, Intel Core i3TM processor, Intel XeonTM processor, AMD OpteronTM processor, Samsung 32-bit RISC ARM 1176JZ(F)-S v1.0TM processor, ARM Cortex-A8 Samsung S5PC100TM processor, ARM Cortex-A8 Apple A4TM processor, Marvell PXA 930TM processor, or a functionally-equivalent processor. Multiple threads of execution can be used for parallel processing.
- multiple processors or processors with multiple cores can be used, whether in a single computer system, in a cluster, or distributed across systems over a network comprising a plurality of computers, cell phones, tablet computing devices, watch based devices, wrist band devices, armband devices, or personal data assistant devices.
- a high speed cache 801 can be connected to, or incorporated in, the processor 802 to provide a high speed memory for instructions or data that have been recently, or are frequently, used by processor 802 .
- the processor 802 is connected to a north bridge 806 by a processor bus 805 .
- the north bridge 806 is connected to random access memory (RAM) 803 by a memory bus 804 and manages access to the RAM 803 by the processor 802 .
- the north bridge 806 is also connected to a south bridge 808 by a chipset bus 807 .
- the south bridge 808 is, in turn, connected to a peripheral bus 809 .
- the peripheral bus can be, for example, PCI, PCI-X, PCI Express, or other peripheral bus.
- the north bridge and south bridge are often referred to as a processor chipset and manage data transfer between the processor, RAM, and peripheral components on the peripheral bus 809 .
- the functionality of the north bridge can be incorporated into the processor instead of using a separate north bridge chip.
- system 800 can include an accelerator card 812 attached to the peripheral bus 809 .
- the accelerator can include field programmable gate arrays (FPGAs) or other hardware for accelerating certain processing.
- the system 800 includes an operating system for managing system resources; non-limiting examples of operating systems include: Linux, WindowsTM, MACOSTM, BlackBerry OSTM, iOSTM, AndroidTM and other functionally-equivalent operating systems, as well as application software running on top of the operating system.
- system 800 also includes network interface cards (NICs) 810 and 811 connected to the peripheral bus for providing network interfaces to external storage, such as Network Attached Storage (NAS) and other computer systems that can be used for distributed parallel processing.
- NICs network interface cards
- NAS Network Attached Storage
- FIG. 9 is a diagram showing a network 900 with a plurality of computer systems 902 a , and 902 b , a plurality of cell phones and personal data assistants 902 c , and Network Attached Storage (NAS) 901 a , and 901 b .
- systems 902 a , 902 b , and 902 c can manage data storage and optimize data access for data stored in Network Attached Storage (NAS) 901 a and 902 b .
- NAS Network Attached Storage
- a mathematical model can be used for the data and be evaluated using distributed parallel processing across computer systems 902 a , and 902 b , and cell phone and personal data assistant systems 902 c .
- Computer systems 902 a , and 902 b , and cell phone and personal data assistant systems 902 c can also provide parallel processing for adaptive data restructuring of the data stored in Network Attached Storage (NAS) 901 a and 901 b .
- FIG. 9 illustrates an example only, and a wide variety of other computer architectures and systems can be used in conjunction with the various embodiments of the present invention.
- a blade server can be used to provide parallel processing.
- Processor blades can be connected through a back plane to provide parallel processing.
- Storage can also be connected to the back plane or as Network Attached Storage (NAS) through a separate network interface.
- NAS Network Attached Storage
- processors can maintain separate memory spaces and transmit data through network interfaces, back plane, or other connectors for parallel processing by other processors. In some embodiments, some or all of the processors can use a shared virtual address memory space.
- FIG. 10 is a block diagram of a multiprocessor computer system using a shared virtual address memory space.
- the system includes a plurality of processors 1001 a - f that can access a shared memory subsystem 1002 .
- the system incorporates a plurality of programmable hardware memory algorithm processors (MAPs) 1003 a - f in the memory subsystem 1002 .
- MAPs programmable hardware memory algorithm processors
- Each MAP 1003 a - f can comprise a memory 1004 a - f and one or more field programmable gate arrays (FPGAs) 1005 a - f .
- the MAP provides a configurable functional unit and particular algorithms or portions of algorithms can be provided to the FPGAs 1005 a - f for processing in close coordination with a respective processor.
- each MAP is globally accessible by all of the processors for these purposes.
- each MAP can use Direct Memory Access (DMA) to access an associated memory 1004 a - f , allowing it to execute tasks independently of, and asynchronously from, the respective microprocessor 1001 a - f .
- DMA Direct Memory Access
- a MAP can feed results directly to another MAP for pipelining and parallel execution of algorithms.
- the above computer architectures and systems are examples only, and a wide variety of other computer, cell phone, and personal data assistant architectures and systems can be used in connection with example embodiments, including systems using any combination of general processors, co-processors, FPGAs and other programmable logic devices, system on chips (SOCs), application specific integrated circuits (ASICs), and other processing and logic elements.
- Any variety of data storage media can be used in connection with example embodiments, including random access memory, hard drives, flash memory, tape drives, disk arrays, Network Attached Storage (NAS) and other local or distributed data storage devices and systems.
- the computer system can be implemented using software modules executing on any of the above or other computer architectures and systems.
- the functions of the system can be implemented partially or completely in firmware, programmable logic devices such as field programmable gate arrays (FPGAs) as referenced in FIG. 10 , system on chips (SOCs), application specific integrated circuits (ASICs), or other processing and logic elements.
- FPGAs field programmable gate arrays
- SOCs system on chips
- ASICs application specific integrated circuits
- the Set Processor and Optimizer can be implemented with hardware acceleration through the use of a hardware accelerator card, such as accelerator card 812 illustrated in FIG. 8 .
- any embodiment of the invention described herein can be, for example, produced and transmitted by a user within the same geographical location.
- a product of the invention can be, for example, produced and/or transmitted from a geographic location in one country and a user of the invention can be present in a different country.
- the data accessed by a system of the invention is a computer program product that can be transmitted from one of a plurality of geographic locations 1101 to a user 1102 ( FIG. 11 ).
- Data generated by a computer program product of the invention can be transmitted back and forth among a plurality of geographic locations, for example, by a network, a secure network, an insecure network, an internet, or an intranet.
- an ontological hierarchy provided by the invention is encoded on a physical and tangible product.
- any embodiment of the invention described herein can be produced and/or transmitted in an encoded form, for example, a radio frequency identification tag or barcode.
- the data accessed by a system of the invention can be accessed from the encoded form either directly or as part of a health record.
- the health record can be an electronic health record or digital health record.
- the health record can be accessed by the subject or a health care provider for the subject.
- FIG. 14 panel A.
- a human subject stands or sits in a way that they can avoid shaking their body.
- the subject holds a radar device attached to their body using either their hand or a chest strap.
- An ECG is simultaneously recorded by a three-electrode ECG circuit with three electrodes attached to a wrist and the left and right ankles.
- the device and ECG circuit is connected to a computer that performs the signal processing and waveform display.
- the device can be disposed in various positions on the subject's chest, resulting in differences in the efficacy and output.
- the device can also be put against the back of the human subject to record data.
- the human subject is in a comfortable and warm environment and is relaxed.
- the subject can stand, sit, walk or lie down on a bed.
- the device can be positioned to contact the skin or can be placed outside the subject's clothing. In the clothed setting, the device can be placed tightly against chest of the subject.
- FIG. 15 panel A shows the ECG signal on the top graph and the radar signal on the bottom graph detected in a healthy young man.
- FIG. 15 panel B shows the ECG signal on the top graph and the radar signal on the bottom graph detected in a healthy elderly man.
- FIG. 15 panel C shows the ECG signal on the top graph and the radar signal on the bottom graph detected in an elderly man with an irregular heartbeat, who is in atrial fibrillation.
- the small first pulse was generated by the motion of the atrium and the larger second pulse was generated by the motion of the ventricles.
- the radar signals from the invention correlated with the ECG signals and were in the same periodicity as the ECG signals.
- panel C the radar signal correlated with the ECG signal but showed little evidence of atrial motion.
- FIG. 16 shows the ECG signal on the top graph and the radar signal on the bottom graph detected in the healthy young man in Example 5 while breathing.
- the additional low frequency signal superimposed on the radar heart motion signal represents the motion of the chest cavity as a result of breathing.
- FIG. 17 shows the ECG signal on the top graph and the radar signal on the bottom graph when a representative device of the invention was positioned at different locations on the chest of the healthy young man from Example 5.
- Panel A illustrates the ECG and radar signals measured at the center of the chest.
- Panel B illustrates the ECG and radar signals measured above the center of the chest
- Panel C illustrates the ECG and radar signals measured below the center of the chest.
- Panel D illustrates the ECG and radar signals measured left of the center of the chest.
- Panel E illustrates the ECG and radar signals measured right of the center of the chest.
- FIG. 18 shows the ECG signal on the top graph and the radar signal on the bottom graph obtained when a device of the invention was positioned on the back of the healthy young man from Example 5. These data represent measurements of atrial motion by positioning the device on the back of the subject.
- Example 9 Subject Measurements at a Distance
- FIG. 21 shows three measurements taken from a healthy male subject at different distances. All of these data were taken with the subject in a held breath state. These data represent measurements of atrial motion by positioning an embodiment of the invention at a distance from the subject.
- FIG. 19 panel A illustrates an embodiment of a device to determine the motion of the heart of a subject.
- the radar system 1901 connected to an antenna 1902 propagates a transmitted waveform 1903 towards a target 1904 , for example, a heart of a subject.
- a reflected waveform 1905 is then received by the antenna 1902 .
- the distance between the antenna 1902 and the target 1904 is defined by the function 1906 d - x ( t ), where d is a constant distance between the antenna 1902 and the target 1904 and x(t) is the motion function of the target 1904 , for example, the original motion of the heart of the subject.
- Panels B-D represent measured waveforms at three different distances between the antenna 1902 and target 1904 .
- the radar system 1901 transmits a cosine signal written as
- T ( t ) A ⁇ cos(2 ⁇ ft);
- A is the amplitude of the transmitted waveform 1903
- f is the frequency of transmitted waveform 1903
- t is time.
- the reflected signal is written as
- R ⁇ ( t ) B ⁇ cos ⁇ ( 2 ⁇ ⁇ ft - 4 ⁇ ⁇ ⁇ d ⁇ - 4 ⁇ ⁇ ⁇ x ⁇ ( t ) ⁇ ) ;
- B is the amplitude of the reflected waveform 1905 and lambda is the wavelength of reflected waveform 1905 .
- I in-phase signal
- Q quadrature signal
- I ⁇ ( t ) C ⁇ cos ⁇ ( 4 ⁇ ⁇ ⁇ d ⁇ + 4 ⁇ ⁇ ⁇ x ⁇ ( t ) ⁇ ) ;
- Y ⁇ ( t ) tan ⁇ ( 4 ⁇ ⁇ ⁇ d ⁇ + 4 ⁇ ⁇ ⁇ x ⁇ ( t ) ⁇ ) .
- x ⁇ ( t ) ⁇ 4 ⁇ ⁇ ⁇ tan - 1 ⁇ ( Y ⁇ ( t ) ) - d .
- Quadrature demodulation as described herein can allow for precise calculation of the motion function of the target 1904 , since motion of the target 1904 is quite small compared with the wavelength of the reflected waveform 1905 .
- FIG. 20 illustrates an embodiment of the method of continuous monitoring described in the invention.
- a subject can wear a device continuously for long-term monitoring 2001 to determine the percentage of cardiac arrhythmic time 2002 .
- These data are recorded and stored over long periods of time, for example, hours, days, weeks, or months.
- Signal recognition software detects and highlights important events for review by a health care provider.
- the health care provider uses the percentage of cardiac arrhythmic time 2002 to determine the appropriate medical intervention 2003 .
- Non-limiting examples of medical interventions include continued monitoring; cardioversion with or without specific pharmaceuticals; cardiac ablation with or without specific pharmaceuticals; and cardiac ablation with or without introduction of a pacemaker.
- Embodiment 1 A method of detecting an irregular heartbeat in a subject, the method comprising: a) transmitting a wavelength of electromagnetic radiation to the heart of the subject; b) detecting an electromagnetic signal reflected off the heart of the subject; and c) determining based on the electromagnetic signal reflected off the heart of the subject whether the subject has an irregular heartbeat.
- Embodiment 2 The method of Embodiment 1, wherein the subject is undergoing an intervention for the irregular heartbeat, the method further comprising determining based on the electromagnetic signal reflected off the heart of the subject whether the intervention for the irregular heartbeat has modulated the irregular heartbeat.
- Embodiment 3 The method of Embodiment 1, wherein the subject is undergoing an intervention for a non-irregular heartbeat condition, the method further comprising determining based on the electromagnetic signal reflected off the heart of the subject whether the intervention for the non-irregular heartbeat condition has induced the irregular heartbeat.
- Embodiment 4 The method of any one of Embodiments 1-3, wherein the determination whether the subject has an irregular heartbeat is determined by an analysis of a movement of a portion of the heart.
- Embodiment 5 The method of any one of Embodiments 1-4, further comprising attaching a source of electromagnetic radiation to the subject's body.
- Embodiment 6 The method of Embodiment 5, wherein the source of electromagnetic radiation is attached to the subject's body in proximity to the subject's heart.
- Embodiment 7 The method of Embodiment 5, wherein the source of electromagnetic radiation is attached to the subject's chest.
- Embodiment 8 The method of Embodiment 5, wherein the source of electromagnetic radiation is attached to the subject's back.
- Embodiment 9 The method of any one of Embodiments 1-8, wherein the subject is in a held-breath state.
- Embodiment 10 The method of any one of Embodiments 1-9, wherein the wavelength of electromagnetic radiation transmitted to the heart of the subject is a radio wave.
- Embodiment 11 The method of any one of Embodiments 1-10, wherein the irregular heartbeat is associated with atrial fibrillation.
- Embodiment 12 The method of any one of Embodiments 1-10, wherein the irregular heartbeat is associated with atrial flutter.
- Embodiment 13 The method of any one of Embodiments 1-10, wherein the irregular heartbeat is associated with ventricular fibrillation.
- Embodiment 14 The method of any one of Embodiments 1-10, wherein the irregular heartbeat is associated with ventricular flutter.
- Embodiment 15 The method of any one of Embodiments 1-10, wherein the irregular heartbeat is associated with cardiac arrhythmia.
- Embodiment 16 The method of any one of Embodiments 1-15, wherein the subject is human.
- Embodiment 17 A method comprising: a) receiving by a computer system data associated with an electromagnetic signal reflected off a heart of a subject; b) comparing by a processor of the computer system the data associated with the electromagnetic signal reflected off the heart of the subject to a reference; c) determining based on the comparison of the data associated with the electromagnetic signal reflected off the heart of the subject to the reference whether the subject has an irregular heartbeat; and d) outputting a result of the determination.
- Embodiment 18 The method of Embodiment 17, wherein the subject is undergoing an intervention for the irregular heartbeat, the method further comprising determining based on the electromagnetic signal reflected off the heart of the subject whether the intervention for the irregular heartbeat has modulated the irregular heartbeat.
- Embodiment 19 The method of Embodiment 17, wherein the subject is undergoing an intervention for a non-irregular heartbeat condition, the method further comprising determining based on the electromagnetic signal reflected off the heart of the subject whether the intervention for the non-irregular heartbeat condition has induced the irregular heartbeat.
- Embodiment 20 The method of any one of Embodiments 17-19, wherein the determination that the subject has an irregular heartbeat is determined by an analysis of a movement of a portion of the heart.
- Embodiment 21 The method of any one of Embodiments 17-20, wherein the irregular heartbeat is associated with atrial fibrillation.
- Embodiment 22 The method of any one of Embodiments 17-20, wherein the irregular heartbeat is associated with atrial flutter.
- Embodiment 23 The method of any one of Embodiments 17-20, wherein the irregular heartbeat is associated with ventricular fibrillation.
- Embodiment 24 The method of any one of Embodiments 17-20, wherein the irregular heartbeat is associated with ventricular flutter.
- Embodiment 25 The method of any one of Embodiments 17-20, wherein the irregular heartbeat is associated with cardiac arrhythmia.
- Embodiment 26 The method of any one of Embodiments 17-25, wherein the subject is human.
- Embodiment 27 A device comprising: a) an antenna configured to transmit electromagnetic radiation into a thoracic cavity of a subject; b) a receiver configured to detect an electromagnetic signal reflected off the subject's heart; and c) a processor configured to identify an irregular heartbeat in the subject based on the detected electromagnetic signal reflected off the subject's heart.
- Embodiment 28 The device of Embodiment 27, wherein the antenna configured to transmit the electromagnetic radiation into the thoracic cavity of the subject, the receiver configured to detect the electromagnetic signal reflected off the subject's heart, and the processor configured to identify the irregular heartbeat in the subject based on the detected electromagnetic signal reflected off the subject's heart, are contained in a common housing.
- Embodiment 29 The device of any one of Embodiments 27-28, further comprising a circuit configured to generate a signal suitable for transmission into the thoracic cavity of the subject by the antenna.
- Embodiment 30 The device of any one of Embodiments 27-29, wherein the processor is configured to detect the irregular heartbeat in a subject by measuring time intervals among signals received after reflection off the subject's heart.
- Embodiment 31 The device of any one of Embodiments 27-30, wherein the antenna is configured to transmit electromagnetic radiation that is a radio wave.
- Embodiment 32 The device of any one of Embodiments 27-31, wherein the device is configured to be attached to the subject in proximity to the subject's heart.
- Embodiment 33 The device of any one of Embodiments 27-32, wherein the device is configured to be attached to the subject on the subject's chest.
- Embodiment 34 The device of any one of Embodiments 27-32, wherein the device is configured to be attached to the subject on the subject's back.
- Embodiment 35 The device of any one of Embodiments 24-34, wherein the processor is configured to identify an irregular heartbeat associated with atrial fibrillation.
- Embodiment 36 The device of any one of Embodiments 24-34, wherein the processor is configured to identify an irregular heartbeat associated with atrial flutter.
- Embodiment 37 The device of any one of Embodiments 24-34, wherein the processor is configured to identify an irregular heartbeat associated with ventricular fibrillation.
- Embodiment 38 The device of any one of Embodiments 24-34, wherein the processor is configured to identify an irregular heartbeat associated with ventricular flutter.
- Embodiment 39 The device of any one of Embodiments 24-34, wherein the processor is configured to identify an irregular heartbeat associated with cardiac arrhythmia.
- Embodiment 40 A device comprising: a) an antenna configured to transmit electromagnetic radiation into a thoracic cavity of a subject; b) a receiver configured to detect an electromagnetic signal reflected off the subject's heart; and c) a transmitter configured to transmit data associated with the received electromagnetic signal reflected off the subject's heart.
- Embodiment 41 The device of Embodiment 40, wherein the antenna configured to transmit the electromagnetic radiation into the thoracic cavity of the subject, the receiver configured to detect the electromagnetic signal reflected off the subject's heart, and the transmitter configured to transmit data associated with the received electromagnetic signal reflected off the subject's heart, are contained in a common housing.
- Embodiment 42 The device of any one of Embodiments 40-41, further comprising a circuit configured to generate a signal suitable for transmission into the thoracic cavity of the subject by the antenna.
- Embodiment 43 The device of any one of Embodiments 40-42, wherein the transmitter is configured to transmit wirelessly to a remote processor.
- Embodiment 44 The device of any one of Embodiments 40-43, wherein the antenna is configured to transmit electromagnetic radiation that is a radio wave.
- Embodiment 45 The device of any one of Embodiments 40-44, wherein the device is configured to be attached to the subject in proximity to the subject's heart.
- Embodiment 46 The device of any one of Embodiments 40-45, wherein the device is configured to be attached to the subject on the subject's chest.
- Embodiment 47 The device of any one of Embodiments 40-45, wherein the device is configured to be attached to the subject on the subject's back.
- Embodiment 48 A method comprising: a) administering to a subject having an irregular heartbeat an intervention for the irregular heartbeat; b) monitoring the subject with a radar device; and c) determining based on the monitoring whether the intervention for the irregular heartbeat modulates the irregular heartbeat in the subject.
- Embodiment 49 The method of Embodiment 48, wherein the radar device monitors a movement of a portion of the subject's heart.
- Embodiment 50 The method of any one of Embodiments 48-49, wherein the processor is configured to identify an irregular heartbeat associated with atrial fibrillation.
- Embodiment 51 The method of any one of Embodiments 48-49, wherein the processor is configured to identify an irregular heartbeat associated with atrial flutter.
- Embodiment 52 The method of any one of Embodiments 48-49, wherein the processor is configured to identify an irregular heartbeat associated with ventricular fibrillation.
- Embodiment 53 The method of any one of Embodiments 48-49, wherein the processor is configured to identify an irregular heartbeat associated with ventricular flutter.
- Embodiment 54 The method of any one of Embodiments 48-49, wherein the processor is configured to identify an irregular heartbeat associated with cardiac arrhythmia.
- Embodiment 55 A method comprising: a) administering to a subject an intervention; b) monitoring the subject with a radar device; and c) determining based on the monitoring whether the intervention induces an irregular heartbeat in the subject.
- Embodiment 56 The method of Embodiment 55, wherein the radar device monitors a movement of a portion of the subject's heart.
- Embodiment 57 The method of any one of Embodiments 55-56, wherein the processor is configured to identify an irregular heartbeat associated with atrial fibrillation.
- Embodiment 58 The method of any one of Embodiments 55-56, wherein the processor is configured to identify an irregular heartbeat associated with atrial flutter.
- Embodiment 59 The method of any one of Embodiments 55-56, wherein the processor is configured to identify an irregular heartbeat associated with ventricular fibrillation.
- Embodiment 60 The method of any one of Embodiments 55-56, wherein the processor is configured to identify an irregular heartbeat associated with ventricular flutter.
- Embodiment 61 The method of any one of Embodiments 55-56, wherein the processor is configured to identify an irregular heartbeat associated with cardiac arrhythmia.
- Embodiment 62 The method of any one of Embodiments 55-61, wherein the subject has a non-irregular heartbeat condition, and the intervention is for the non-irregular heartbeat condition.
- Embodiment 63 A method comprising: a) transmitting a wavelength of electromagnetic radiation to the heart of the subject; b) detecting an electromagnetic signal reflected off the heart of the subject; and c) determining based on the electromagnetic signal reflected off the heart of the subject a change in volume of the heart of the subject.
- Embodiment 64 The method of Embodiment 63, further comprising determining a volume of blood output from the heart of the subject based on the change in volume of the heart of the subject.
- Embodiment 65 The method of any one of Embodiments 63-64, wherein the change in volume of the heart of the subject is determined within a single chamber of the heart of the subject.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Artificial Intelligence (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Signal Processing (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Dentistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 14/736,745, filed Jun. 11, 2015, which claims the benefit of priority to U.S. Provisional Patent Application Ser. No. 62/010,653, filed on Jun. 11, 2014, and U.S. Provisional Patent Application Ser. No. 62/145,649, filed on Apr. 10, 2015, each of which is hereby incorporated by reference in its entirety.
- The invention was made with the support of the United States government under the Small Business Technology Transfer Award 1449060 by the National Science Foundation. The government may have certain rights in the invention.
- The development of cardiac testing and monitoring devices that can be used in the home has the potential to reduce healthcare costs, increase patient compliance, and improve the quality of life of patients. The elderly, incapacitated, and those without easy access to healthcare facilities can greatly benefit from home testing devices. However, current home testing devices are often uncomfortable, difficult to use, and expensive. Several challenges still exist in the creation of cost-effective, simple-to-use, and accurate home testing.
- In some embodiments, the invention provides a method of detecting an irregular heartbeat in a subject, the method comprising: a) transmitting a wavelength of electromagnetic radiation to the heart of the subject; b) detecting an electromagnetic signal reflected off the heart of the subject; and c) determining based on the electromagnetic signal reflected off the heart of the subject whether the subject has an irregular heartbeat.
- In some embodiments, the invention provides a method comprising: a) receiving by a computer system data associated with an electromagnetic signal reflected off a heart of a subject; b) comparing by a processor of the computer system the data associated with the electromagnetic signal reflected off the heart of the subject to a reference; c) determining based on the comparison of the data associated with the electromagnetic signal reflected off the heart of the subject to the reference whether the subject has an irregular heartbeat; and d) outputting a result of the determination.
- In some embodiments, the invention provides a device comprising: a) an antenna configured to transmit electromagnetic radiation into a thoracic cavity of a subject; b) a receiver configured to detect an electromagnetic signal reflected off the subject's heart; and c) a processor configured to identify an irregular heartbeat in the subject based on the detected electromagnetic signal reflected off the subject's heart.
- In some embodiments, the invention provides a device comprising: a) an antenna configured to transmit electromagnetic radiation into a thoracic cavity of a subject; b) a receiver configured to detect an electromagnetic signal reflected off the subject's heart; and c) a transmitter configured to transmit data associated with the received electromagnetic signal reflected off the subject's heart.
- In some embodiments, the invention provides a method comprising: a) administering to a subject having an irregular heartbeat an intervention for the irregular heartbeat; b) monitoring the subject with a radar device; and c) determining based on the monitoring whether the intervention for the irregular heartbeat modulates the irregular heartbeat in the subject.
- In some embodiments, the invention provides a method comprising: a) administering to a subject an intervention; b) monitoring the subject with a radar device; and c) determining based on the monitoring whether the intervention induces an irregular heartbeat in the subject.
-
FIG. 1 depicts a representative device of the invention. -
FIG. 2 shows comparative ECGs for atrial fibrillation and a normal heartbeat. -
FIG. 3 is a representative ECG for atrial flutter. -
FIG. 4 is a representative ECG for ventricular fibrillation. -
FIG. 5 depicts a function of an example device of the invention. -
FIG. 6 illustrates the thickness of different tissues in the human body. -
FIG. 7 depicts signal loss inside human tissue. -
FIG. 8 is a block diagram illustrating a first example architecture of a computer system that can be used in connection with example embodiments of the present invention. -
FIG. 9 is a diagram illustrating a computer network that can be used in connection with example embodiments of the present invention. -
FIG. 10 is a block diagram illustrating a second example architecture of a computer system that can be used in connection with example embodiments of the present invention. -
FIG. 11 illustrates a global network that can transmit a product of the invention. -
FIG. 12 depicts a representative device of the invention. -
FIG. 13 depicts a representative device of the invention. -
FIG. 14 illustrates representative implementations of an example device of the invention. -
FIG. 15 is paired ECGs and measurements with a representative device of the invention in human subjects. -
FIG. 16 is a paired ECG and measurement with a representative device of the invention in a human subject. -
FIG. 17 is paired ECGs and measurements with a representative device of the invention in a human subject. -
FIG. 18 is a paired ECG and measurement with a representative device of the invention in a human subject. -
FIG. 19 depicts a representative device of the invention and measured waveforms from the representative radar device. -
FIG. 20 illustrates a method of monitoring that can be used in connection with example embodiments of the present invention. -
FIG. 21 depicts measured waveforms from the representative radar device. - Portable testing devices have the potential to reduce healthcare costs and improve the delivery of healthcare to patients who do not have immediate or easy access to healthcare facilities. A portable heart motion monitor can rapidly and conveniently determine the cardiac status of patients without requiring travel to a hospital or doctor's office. This convenience can reduce costs by reducing frequency of hospital visits and improving diagnosis rates due to increased patient compliance. A compact and portable heart motion monitor provides a special benefit to patients who are elderly, incapacitated, or living in remote areas, who would otherwise have to travel tediously to receive adequate healthcare. The invention described herein provides a simple, cost-effective, and efficient method to obtain information about a patient's heart from anywhere that the patient goes, even in the comfort of the patient's home.
- Described herein are methods and devices to measure an irregular heartbeat in a subject. A mobile device of the invention can be used in a subject's home without clinical intervention. The device described herein can detect heart motion in a subject continuously and non-invasively. The device can be worn by the subject, attached to the subject, mounted, stationary, or otherwise convenient for outpatient use.
- An irregular heartbeat, also known as cardiac dysrhythmia or arrhythmia, is any of a group of conditions wherein the electrical activity of the heart is irregular and often faster or slower than is normal. An irregular heartbeat can be symptomatic of deeper underlying cardiac conditions. The standard diagnostic test for arrhythmias is electrocardiography (ECG). An ECG is a recording of the electrical activity of the heart, the output of which is a series of waveforms corresponding to the electrical impulses generated by the polarization and depolarization of cardiac tissue, known as an electrocardiogram (also ECG). While an ECG is a powerful method to glean a variety of information about a patient's cardiac status, the test requires a significant amount of clinical expertise and a visit to the clinic or hospital. This inconvenience makes the process of obtaining an ECG unappealing, especially if the patient is elderly, incapacitated, or resides in a rural area where access to a clinic can be difficult.
- Diagnosis of an irregular heartbeat can be essential in determining underlying cardiac abnormalities or disease. Subjects with atrial fibrillation, for example, can have a higher risk of stroke due to the pooling of blood in atria, which can lead to blood clots. Thus, development of devices that can rapidly and easily monitor cardiac activity can lead to efficient and effective diagnoses of cardiac conditions. Devices that can be used remotely can increase patient compliance, thereby improving diagnosis success rates.
- A device described herein can be worn by a subject to monitor cardiac activity in various environments. Activity can be monitored in a care setting, such as a clinic, hospital, or doctor's office, or in a place away from a clinic or a hospital, for example, at home, at school, or any place where the user wishes to wear the device. A device described herein can also be used during everyday activity, for example, while driving a car, doing daily errands, exercising, shopping, or during periods of rest or sleep. The device described herein can use, for example, electromagnetic signals to determine the motion of a subject's heart to monitor and diagnose the heart for irregularities.
- A device described herein can be used during short-term visits to a clinic, hospital, or doctor's office. The device can also be used by a subject during an inpatient visit to a hospital, or while a subject is recovering in a hospital, but needs the freedom to be ambulatory.
-
FIG. 1 illustrates adevice 101 to determine the motion of the heart of a subject. Thetransmitter 102 of thetransceiver circuit 109 generates a signal that is routed to anantenna 105 via theduplexer 104. The signal can then propagate 108 from the antenna to an object ofinterest 106, such as a heart of portion thereof. The signal can be, for example, pulsed or continuous. In some embodiments, the signal is electromagnetic radiation such as a radio wave, an electromagnetic signal, a wavelength or frequency of the electromagnetic spectrum, a wavelength of light, or a photon. After transmission of the signal, the signal can be reflected 107 off the object ofinterest 106, such as the heart. The signal is detected by theantenna 105 and routed to thereceiver 103 via theduplexer 104. In some embodiments, the device comprises a radar system. Non-limiting examples of the types of radar that can be used in the device include ultrawide bandwidth radar, continuous wave Doppler radar, pulsed Doppler radar, frequency-modulated continuous wave radar, or pseudorandom code modulated continuous wave radar. -
FIG. 12 illustrates an embodiment of a device to determine the motion of the heart of a subject. Thepulse generator 1201 generates apulse 1202 that is routed through a pulsedsine wave generator 1203 to generate apulse waveform 1204. Thepulse waveform 1204 is then routed to theantenna 1206 via theduplexer 1205. Thepulse waveform 1204 can then propagate from theantenna 1206 to atarget 1207, such as a heart of portion thereof. In some embodiments, thepulse waveform 1204 is electromagnetic radiation such as a radio wave, an electromagnetic signal, a wavelength or frequency of the electromagnetic spectrum, a wavelength of light, or a photon. After transmission of thepulse waveform 1204, thepulse waveform 1204 can be reflected off thetarget 1207, such as the heart. Thepulse waveform 1204 is detected by theantenna 1206 and routed to themixer 1209 via theduplexer 1205, which converts the detected pulse waveform into aduplexed waveform 1208. Theduplexed waveform 1208 is propagated from themixer 1209 to the amplifier andfilters 1210 to generate the filteredwaveform 1211. The filteredwaveform 1211 is then propagated to the signal processing anddisplay unit 1212. In some embodiments, the device comprises a radar system. Non-limiting examples of the types of radar that can be used in the device include ultrawide bandwidth radar, continuous wave Doppler radar, pulsed Doppler radar, frequency-modulated continuous wave radar, and pseudorandom code modulated continuous wave radar. - In some embodiments, multiple radar sensors can be used to increase the accuracy of the cardiac measurements. Multiple radar sensors also measure heart motion profiles from different positions of view and generate a multi-dimensional data set that can be inverted to solve for the motion of the heart in two dimensions. This method can provide accurate measurements by reducing the effect of random movement or misalignment of individual radar sensors.
-
FIG. 13 illustrates an embodiment of a device to determine the motion of the heart of a subject. Within a printedcircuit board 1301, a voltage controlledoscillator 1302 generates a waveform. The waveform is then propagated through asplitter 1303 and afirst amplifier 1304 to thecirculator 1305. The waveform is then carried from acirculator 1305 to anantenna 1306. A reflected waveform is then carried from theantenna 1306 to thecirculator 1305. The waveform is then propagated to asecond amplifier 1307. The waveform is then filtered through abandpass filter 1308. The filtered waveform is then decoded using aquadrature demodulation chip 1309. The decoded waveform is then transmitted to asignal acquisition unit 1310. In some embodiments, the device comprises a radar system. Non-limiting examples of the types of radar that can be used in the device include ultrawide bandwidth radar, continuous wave Doppler radar, pulsed Doppler radar, frequency-modulated continuous wave radar, and pseudorandom code modulated continuous wave radar. - In some embodiments, a device described herein comprises a monostatic radar architecture, wherein only one antenna is used for both transmission and reception. In some embodiments, a device described herein comprises a duplexer, which can separate transmitted and received signals when one antenna is used for both transmission and reception. In a monostatic radar system, signals generated are passed directly to the antenna, while received signals from the antenna are routed to the receiver portion. A duplexer can provide isolation between the transmit and receive paths, allowing for one antenna to perform both functions.
- In some embodiments, a device described herein comprises a bistatic radar architecture. In a device comprising a bistatic radar architecture, two antennas are spatially separated for the transmit and receive paths.
- Non-limiting examples of antennae that can be used in the device include an isotropic radiator, a dipole antenna, a Yagi-Uda antenna, a random wire antenna, a horn antenna, a parabolic antenna, and a patch antenna. In some embodiments, the antenna can be detachable or removable from the device. In some embodiments, the antenna can be interchangeable or exchangeable for a different antenna, for example, an antenna of a differing strength. The antenna can be placed, for example, inside, outside, in proximity to, adjacent to, on top of, or below the device.
- In some embodiments, the device can determine if the subject has a condition associated with an irregular heartbeat. Non-limiting examples of conditions associated with an irregular heartbeat include paroxysmal atrial fibrillation, paroxysmal atrial flutter, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter, supraventricular tachycardia, Wolff-Parkinson-White syndrome, premature ventricular contraction, premature atrial contraction, sick sinus syndrome, sinus arrhythmia, sinus tachycardia, multifocal atrial tachycardia, or bradycardia.
- A device can comprise a computer system that can receive data associated with a signal reflecting off the subject's heart. The data that is received by the computer system can then be compared by a processor of the computer system to a reference to determine if the subject has an irregular heartbeat. Non-limiting examples of references that can be used by the computer system include past measurements from the subject, measurements from a healthy subject, statistical averages of the symptom being measured, and reference texts. The computer system can then output a result of the determination. In some embodiments, the processor is located in a housing common to the source of the signal in the device. In some embodiments, the processor is not located in a housing common to the source of the signal in the device.
- In some embodiments, the device comprises a processor coupled to a transmitter configured to transmit data from the device to a remote location, for example, a hospital, a clinic, or a doctor's office. The transmitter can be configured to transmit data wirelessly, for example, via Bluetooth, wireless networks, cell phone networks, a cloud network, or the internet. For example, the device can use Bluetooth to connect to an analysis device, including but not limited to, a cell phone or computer system. In some embodiments, the transmission is wired. The processor can be configured to transmit data to a plurality of receivers in a plurality of geographic locations. In some embodiments, the processor can transmit data over a distance of about 1 mile, about 2 miles, about 3 miles, about 4 miles, about 5 miles, about 6 miles, about 7 miles, about 8 miles, about 9 miles, or about 10 miles. In some embodiments, the processor can transmit data over a distance of at least 10 miles. In some embodiments, the processor can transmit data over a distance of at least 50 miles. In some embodiments, the device comprises a Global Positioning System (GPS).
- A device described herein can be, or cannot be, worn by a subject. The device can be attached to a subject's body using, for example, a chest strap, a chest vest, an arm band, a wrist band, a headband, a belt, an adhesive tape, or glue. A device described herein can be embedded in a subject's clothing, for example, an undergarment, a bra, a shirt, a jacket, or a sweater. A device described herein can be embedded in, for example, a watch, an earring, a necklace, a ring, or a bracelet. The device can also be unattached from the subject's body. A device described herein can be attached to, for example, a wall, a headboard, a bed, a mirror, a nightstand, a chair, or other furniture in proximity to the subject. The device can be embedded in, for example, a mattress, a pillow, a comforter, or a sofa.
- A device described herein can be, or cannot be, at a distance from a subject. The distance between the device and the subject can be zero, at least about 1 centimeter (cm), at least about 2 cm, at least about 3 cm, at least about 4 cm, at least about 5 cm, at least about 6 cm, at least about 7 cm, at least about 8 cm, at least about 9 cm, at least about 10 cm, at least about 11 cm, at least about 12 cm, at least about 13 cm, at least about 14 cm, at least about 15 cm, at least about 16 cm, at least about 17 cm, at least about 18 cm, at least about 19 cm, at least about 20 cm, at least about 21 cm, at least about 22 cm, at least about 23 cm, at least about 24 cm, at least about 25 cm, at least about 26 cm, at least about 27 cm, at least about 28 cm, at least about 29 cm, at least about 30 cm, at least about 31, at least about 32 cm, at least about 33 cm, at least about 34 cm, at least about 35 cm, at least about 36 cm, at least about 37 cm, at least about 38 cm, at least about 39 cm, at least about 40 cm, at least about 41 cm, at least about 42 cm, at least about 43 cm, at least about 44 cm, at least about 45 cm, at least about 46 cm, at least about 47 cm, at least about 48 cm, at least about 49 cm, at least about 50 cm, at least about 60 cm, at least about 70 cm, at least about 80 cm, at least about 90 cm, at least about 1 meter (m), at least about 2 m, at least about 3 m, at least about 4 m, at least about 5 m, at least about 6 m, at least about 7 m, at least about 8 m, at least about 9 m, at least about 10 m, at least about 15 m, or at least about 20 m.
- The distance between the device and the subject can be at most about 1 centimeter (cm), at most about 2 cm, at most about 3 cm, at most about 4 cm, at most about 5 cm, at most about 6 cm, at most about 7 cm, at most about 8 cm, at most about 9 cm, at most about 10 cm, at most about 11 cm, at most about 12 cm, at most about 13 cm, at most about 14 cm, at most about 15 cm, at most about 16 cm, at most about 17 cm, at most about 18 cm, at most about 19 cm, at most about 20 cm, at most about 21 cm, at most about 22 cm, at most about 23 cm, at most about 24 cm, at most about 25 cm, at most about 26 cm, at most about 27 cm, at most about 28 cm, at most about 29 cm, at most about 30 cm, at most about 31, at most about 32 cm, at most about 33 cm, at most about 34 cm, at most about 35 cm, at most about 36 cm, at most about 37 cm, at most about 38 cm, at most about 39 cm, at most about 40 cm, at most about 41 cm, at most about 42 cm, at most about 43 cm, at most about 44 cm, at most about 45 cm, at most about 46 cm, at most about 47 cm, at most about 48 cm, at most about 49 cm, at most about 50 cm, at most about 60 cm, at most about 70 cm, at most about 80 cm, at most about 90 cm, at most about 1 meter (m), at most about 2 m, at most about 3 m, at most about 4 m, at most about 5 m, at most about 6 m, at most about 7 m, at most about 8 m, at most about 9 m, at most about 10 m, at most about 15 m, or at most about 20 m.
- A device described herein can be, or cannot be, in contact with a subject's skin. The device can be placed in proximity to, for example, the chest, the sternum, the heart, or the thoracic cavity of a subject. The device can be placed directly on, for example, the chest, the sternum, or the thoracic cavity of a subject. In some embodiments, the device can be placed in the center of the chest, the upper part of the chest, the lower part of the chest, the left part of the center of the chest, or the right part of the center of the chest of a subject. In some embodiments, the device can be placed on the back of a subject, for example, in line with, above, below, left, or right of the sternum. In some embodiments, the device can be placed in front of, for example, the chest, the sternum, or the thoracic cavity of a subject.
- A device described herein can be used by a subject holding breath. In some embodiments, the device can be used by a subject breathing normally.
- A device described herein can be used by a subject hourly, daily, weekly, monthly, yearly, occasionally, frequently, continuously, or chronically. A device described herein can be used by a subject as needed based on a condition of the subject, upon a doctor's recommendation, as desired by the subject, as required to monitor the condition of the subject properly, or for diagnostic or research purposes.
- In some embodiments, a device of the invention has an average output power of about 1 μW, about 2 μW, about 3 μW, about 4 μW, about 5 μW, about 6 μW, about 7 μW, about 8 μW, about 9 μW, about 10 μW, about 20 μW, about 30 μW, about 40 μW, about 50 μW, about 60 μW, about 70 μw, about 80 μW, about 90 μW, about 100 μW, about 200 μW, about 300 μW, about 400 μw, about 500 μW, about 600 μW, about 700 μW, about 800 μW, about 900 μW, about 1 mW, about 2 mW, about 3 mW, about 4 mW, about 5 mW, about 6 mW, about 7 mW, about 8 mW, about 9 mW, about 10 mW, about 15 mW, about 20 mW, about 25 mW, about 30 mW, about 35 mW, about 40 mW, about 45 mW, about 50 mW, about 60 mW, about 70 mW, about 80 mW, about 90 mW, or about 100 mW.
- A device described herein can produce pulses of electromagnetic waves. The duration of the pulses can be about 1 ps, about 2 ps, about 3 ps, about 4 ps, about 5 ps, about 6 ps, about 7 ps, about 8 ps, about 9 ps, about 10 ps, about 20 ps, about 30 ps, about 40 ps, about 50 ps, about 60 ps, about 70 ps, about 80 ps, about 90 ps, about 100 ps, about 110 ps, about 120 ps, about 130 ps, about 140 ps, about 150 ps, about 160 ps, about 170 ps, about 180 ps, about 190 ps, about 200 ps, about 250 ps, about 300 ps, about 350 ps, about 400 ps, about 450 ps, about 500 ps, about 600 ps, about 700 ps, about 800 ps, about 900 ps, about 1 ns, about 2 ns, about 3 ns, about 4 ns, about 5 ns, about 6 ns, about 7 ns, about 8 ns, about 9 ns, about 10 ns, about 20 ns, about 30 ns, about 40 ns, about 50 ns, about 60 ns, about 70 ns, about 80 ns, about 90 ns, about 100 ns, about 200 ns, about 300 ns, about 400 ns, about 500 ns, about 600 ns, about 700 ns, about 800 ns, about 900 ns, or about 1 μs. The repetition rate of the pulses can be about 0.1 MHz, about 0.2 MHz, about 0.3 MHz, about 0.4 MHz, about 0.5 MHz, about 0.6 MHz, about 0.7 MHz, about 0.8 MHz, about 0.9 MHz, about 1 MHz, about 2 MHz, about 3 MHz, about 4 MHz, about 5 MHz, about 6 MHz, about 7 MHz, about 8 MHz, about 9 MHz, about 10 MHz, about 15 MHz, about 20 MHz, about 25 MHz, about 30 MHz, about 35 MHz, about 40 MHz, about 45 MHz, about 50 MHz, about 60 MHz, about 70 MHz, about 80 MHz, about 90 MHz, or about 100 MHz.
- Non-limiting examples of device shape include a cube, a sphere, a cylinder, a square, a rectangle, and a circle. A device described herein can have a height (H), width (W), and depth (D), each independently of about 0.05 inches, about 0.1 inches, about 0.15 inches, about 0.2 inches, about 0.25 inches, about 0.3 inches, about 0.35 inches, about 0.4 inches, about 0.45 inches, about 0.5 inches, about 0.6 inches, about 0.7 inches, about 0.8 inches, about 0.9 inches, or about 1 inch. In some embodiments, the device is a cube. In some embodiments, the device can have dimensions of about 1 inch height by about 1 inch width by about 0.2 inches depth.
- Non-limiting examples of materials that can be used in the manufacture of the device include polyvinyl chloride, polyethylene, polypropylene, polystyrene, polyurethane, polyethylene terephthalate, polycarbonate, silicone, and combinations thereof. Further non-limiting examples of materials that can be used in the manufacture of the device include steel, low-carbon steel, medium-carbon steel, high-carbon steel, aluminum, brass, copper, lead, magnesium, nickel, titanium, zinc, and combinations thereof. Additional non-limiting examples of materials that can be used in the manufacture of the device include copper wire, aluminum wire XHHW wire, THWN wire, and THHN wire.
- Non-limiting examples of chips that can be used in the manufacture of the device include dynamic random access memory chips, microprocessors, application specific integrated circuits, digital signal processors, programmable memory chips, and combinations thereof.
- Non-limiting examples of semiconductors that can be used in the manufacture of the device include diamond, silicon, germanium, tin, silicon carbide, selenium, tellurium, boron nitride, zinc oxide, copper (I) oxide, and combinations thereof.
- In some embodiments, the device has a total mass of less than about 100 grams. The total mass of the device can be about 1 gram, about 2 grams, about 3 grams, about 4 grams, about 5 grams, about 6 grams, about 7 grams, about 8 grams, about 9 grams, about 10 grams, about 15 grams, about 20 grams, about 25 grams, about 30 grams, about 35 grams, about 40 grams, about 45 grams, about 50 grams, about 60 grams, about 70 grams, about 80 grams, about 90 grams, about 100 grams, about 110 grams, about 120 grams, about 130 grams, about 140 grams, about 150 grams, about 200 grams, about 250 grams, about 300 grams, about 350 grams, about 400 grams, about 450 grams, about 500 grams, about 550 grams, about 600 grams, about 650 grams, about 700 grams, about 750 grams, about 800 grams, about 850 grams, about 900 grams, about 950 grams, or about 1000 grams.
- Any tool, interface, engine, application, program, service, command, or other executable item can be provided as a module encoded on a computer-readable medium in computer executable code. In some embodiments, the invention provides a computer-readable medium encoded therein computer-executable code that encodes a method for performing any action described herein, wherein the method comprises providing a system comprising any number of modules described herein, each module performing any function described herein to provide a result, such as an output, to a user.
- The device described herein can be used to monitor the cardiac activity of a subject, and detect abnormalities. The monitoring can detect the motion of the subject's heart. The device can also detect, for example, the relative position of a portion of the heart as compared to the rest of the heart, a movement of the left atrium, a movement of the right atrium, a movement of the left ventricle, a movement of the right ventricle, a change in a dimension of the heart, the heart rate, the pattern of the heart rate, the regularity of the heartbeat, the irregularity of the heartbeat, the strength of the heartbeat, the intensity of the heartbeat, the position of the heart muscles, the velocity of the heart muscles, the relative strength of diastole, the relative strength of systole, the sinus rhythm of the atria, the sinus rhythm of the ventricles, ejection fraction, cardiac output, and stroke volume.
- The device described herein can obtain and record measurements, for example, when the subject is at rest, in motion, doing light exercise, doing heavy exercise, walking, running, jogging, biking, or sleeping. Measurements taken during these times can be compared to readings taken during other times to determine the cardiac activity of the subject.
- A subject can be, for example, an elderly adult, an adult, an adolescent, a child, a toddler, or an infant. A subject can be, for example, an individual with a heart condition or an individual without a heart condition. A subject can be a patient.
- The device described herein can be used to detect an irregular heartbeat in a subject. An irregular heartbeat, also known as cardiac dysrhythmia or arrhythmia, is characterized by an abnormal heart rate or rhythm, and a change in the electrical activity of the heart. An irregular heartbeat can be caused by, for example, coronary artery disease, electrolyte imbalances, scarring of the heart muscle from a previous heart attack, cardiomyopathy, hypertension, diabetes, hyperthyroidism, stress, smoking, medication side effects (for example, chemotherapy-induced cardiotoxicity), excessive consumption of alcohol, excessive consumption of caffeine, or drug abuse. The major symptoms of an irregular heartbeat include, for example, a fluttering sensation in the chest, palpitations, chest pain, shortness of breath, slow heartbeat, shortness of breath, dizziness, and syncope.
- Atrial fibrillation is a common condition associated with an irregular heartbeat, with almost half a million cases diagnosed in the United States annually. In this condition, the normal electrical impulses produced by the sinus node of the heart for a regular heartbeat are overwhelmed by rapid electrical discharges produced in the atria and adjacent parts of the pulmonary veins. These rapid and irregular abnormal discharges can exceed 350 discharges per minute, cause ineffective contractions of the atria, and reduce the ability of the atria to pump blood into the ventricles. These complications further lead to irregular ventricular contractions, causing a discrepancy in the rate of contractions in the atria and ventricles.
-
FIG. 2 shows an ECG for a subject with a normal heart rate and one for a subject with atrial fibrillation. The arrow in the bottom ECG denotes a P wave found in subjects with a normal heartbeat. The P wave on an ECG represents the depolarization that spreads through the sinoatrial node to the atria, also known as atrial depolarization. Atrial depolarization is the first step of the cardiac cycle and occurs when there is an influx of Ca′ ions, which leads to contractions within the atrium. A patient with atrial fibrillation will not have a P wave on an ECG due to the lack of atrial depolarization. In the place of the P wave, small spikes in electrical activity provide evidence of electrical disturbance, as denoted by the arrow in the top ECG. The major symptoms of atrial fibrillation can include palpitations, chest pain, shortness of breath, and syncope. The heart rate can exceed about 100 beats per minute. Paroxysmal atrial fibrillation can be an episode of atrial fibrillation that occurs and then stops and does not happen persistently or consistently. - Atrial flutter is an abnormal heart rhythm that occurs within the atria. Atrial flutter can be caused by a rapid electrical impulse that begins, most commonly, in the right atrium which moves in a localized self-perpetuating loop. The circuit can go around the atria at about 300 beats per minute, in turn causing the ventricles to beat very rapidly. The self-perpetuating loop circles the right atrium and passes through the cavo-tricuspid isthmus, an area of fibrous tissue in the lower atrium between the inferior vena cava and the tricuspid valve. A characteristic ECG of a patient with atrial flutter is shown in
FIG. 3 . The rapid, but regular, beating of the atria can lead to a saw tooth pattern on an ECG. The major symptoms of atrial flutter can include palpitations, shortness of breath, rapid heart rate, chest pain, lightheadedness, fatigue, and low blood pressure. Paroxysmal atrial flutter can be an episode of atrial flutter that occurs and then stops and does not happen persistently or consistently. - Ventricular flutter can be characterized by a rapid heartbeat that originates in the ventricles. Ventricular flutter generally progresses to ventricular fibrillation and is short-lived. Ventricular fibrillation can occur by an uncoordinated contraction in the ventricles, causing a quiver rather than proper contractions. The heartbeat can exceed 350 beats per minute. This improper contraction of the ventricles most often leads to cardiac arrest due to an inability of the ventricles to pump blood through the heart. The most common cause of ventricular fibrillation is coronary artery disease. The most immediate symptoms of ventricular fibrillation are sudden collapse or loss of consciousness, and fainting. Early signs of ventricular fibrillation can include dizziness, nausea, chest pain, rapid heart rate, or palpitations. Generally, if a subject is not treated within five minutes of collapse due to ventricular fibrillation, the subject will undergo cardiac arrest. The erratic heartbeats present during ventricular fibrillation can be seen in the ECG in
FIG. 4 . - Supraventricular tachycardia (SVT) is a rapid heart rate that originates in or above the atrioventricular node. Episodes of SVT can last for a few seconds, minutes, hours, or days. The major symptoms of SVT include a pounding heart, shortness of breath, rapid heartbeat, dizziness, chest pain, and syncope.
- Wolff-Parkinson-White (WPW) syndrome is caused by the presence of an abnormal accessory electrical conduction pathway between the atria and the ventricles. Electrical signals travelling down this abnormal pathway can stimulate the ventricles to contract prematurely, resulting in a unique type of supraventricular tachycardia, referred to as an atrioventricular reciprocating tachycardia. Often, WPW syndrome is asymptomatic, but symptoms can include palpitations, shortness of breath, dizziness, and syncope.
- Premature ventricular contraction (PVC) occurs when a heartbeat is initiated in the Purkinje fibers of the ventricles, rather than the sinoatrial node, where a normal heartbeat originates. PVC is a relatively common event and is generally considered benign, but can indicate hypoxia in the myocardium. PVC most commonly occurs in the elderly and in men, and is generally asymptomatic and difficult to detect without an ECG. Possible signs of a PVC event include palpitations, shortness of breath, dizziness, increased awareness of one's heartbeat, and a feeling of forceful beats.
- Premature atrial contractions (PACs) occur when the heartbeat originates in the atria, rather than the sinoatrial node. PACs are a common event that can manifest in patients without underlying cardiac abnormalities, and are considered fairly benign. PACs are generally asymptomatic, but rarely present with palpitations.
- Sick sinus syndrome (SSS) includes arrhythmias that originate in the sinus node. SSS is often associated with coronary artery disease and valvular lesions. SSS is most common in the elderly and in children who have undergone cardiac surgery in the atria. Symptoms of SSS include syncope, dizziness, shortness of breath, chest pain, fatigue, headache, and nausea.
- Sinus arrhythmia refers to the natural variation in heartbeat that occurs with breathing. A mild slowing and acceleration of heart rate occurs with breathing. Sinus arrhythmia is most pronounced in children and steadily decreases with age.
- Sinus tachycardia is a rapid heart rhythm originating in the sinoatrial node with a heartbeat that can exceed 100 beats per minute. Sinus tachycardia is generally a response to normal physiological situations such an exercise and stress. The main symptom of sinus tachycardia is an increased heart rate.
- Multifocal atrial tachycardia is a cardiac arrhythmia associated with chronic obstructive pulmonary disease (COPD). Multifocal atrial tachycardia occurs when groups of cells outside of the sinoatrial node begin to control the heartbeat, and the heart rate exceeds 100 beats per minute. Symptoms can include tightness in the chest, light-headedness, syncope, palpitations, shortness of breath, and dizziness.
- Bradycardia is a resting heart rate of less than 60 beats per minute, generally remaining asymptomatic until the rate drops below 50 beats per minute. Symptoms of bradycardia include fatigue, weakness, dizziness, and syncope. Bradycardia can be caused by recreational drug use, metabolic or hormonal imbalances, electrolyte imbalances, coronary artery disease, vascular heart disease, or valvular heart disease. Generally, bradycardia can be caused by problems that arise in the sinoatrial node or atrioventricular node.
- A device described herein can be used to determine, observe, record, time, track, or calculate, the burden, or duration, of an irregular heartbeat in a subject. The device can record measurements for a specified period of time to determine the percentage of time the subject has an irregular heartbeat. The device can record measurements for about one minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about one hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 10 hours, about 20 hours, about one day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about one week, about 2 weeks, about 3 weeks, about one month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about one year, about 2 years, or about 3 years. The burden can be determined over any time period by an analysis of the data, comparing episodes of irregular heartbeat to the subject's own ordinary heartbeat or to a reference heartbeat.
- The device described herein can be used to monitor cardiac activity in a subject undergoing an intervention for an irregular heartbeat. The intervention can involve pharmacological agents, devices that are, or are not, implanted in the subject to modulate the heartbeat, surgery, and combinations thereof. The device can be used to determine if the intervention is modulating the irregular heartbeat by comparing readings taken before and after administration of the intervention, or during the course of therapy. Non-limiting examples of interventions used by a subject that can be monitored by the present invention include amiodarone, bepridil hydrochloride, disopyramide, dofetilide, dronedarone, flecainide, ibutilide, lidocaine, procainamide, propafenone, propranolol, quinidine, sotalol, tocainide, amlodipine, diltiazem, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine, verapamil, acebutolol, atenolol, betaxolol, bisoprolol, hydrochlorothiazide, carteolol, esmolol, metoprolol, nadolol, penbutolol, pindolol, timolol, warfarin, dalterparin, enoxaparin, heparin, tinzaparin, aspirin, ticlopidine, clopidogrel, dipyridamole, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, temisartan, valsartan, amiloride, bumetanide, chlorothiazide, chlorthalidone, furosemide, indapamide, spironolactone, isosorbide dinitrate, nesiritide, hydralazine, minoxidil, lanoxin, atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, clofibrate, gemfibrozil, digoxin, adenosine, radiofrequency ablation, transcatheter ablation, defibrillation, a pacemaker, an implantable cardioverter defibrillator, and combinations thereof.
- The device described herein can be used to monitor cardiac activity in a subject undergoing an intervention for a non-irregular heartbeat condition. The intervention can comprise pharmacological agents, surgery, and combinations thereof. The device can be used to determine whether the intervention is inducing an irregular heartbeat by comparing readings taken before and after administration of the intervention, or during the course of therapy. Non-limiting examples of interventions used by a subject that can be monitored by the present invention include diphenhydramine, chlorpheniramine, clemastine, brompheniramine, hydroxyzine, cetirizine, fexofenadine, loratadine, dextroamphetamine, methamphetamine, methylphenidate, fenfluramine, dexfenfluramine, MDMA, cocaine, pseudoephedrine, albuterol, isoproterenol, salmeterol, isoetharine, phencyclidine, tranylcypromine, phenelzine, aminophylline, caffeine, nortriptyline, amitriptyline, imipramine, desipramine, scopolamine, propantheline, atropine, cisapride, erythromycin lactobionate, pentamidine, chloroquine, amantadine, and combinations thereof.
- The device described herein can be used to monitor cardiac activity in a subject undergoing an intervention for a cancer, tumor, hyperproliferative disorder, or neoplasia. The intervention can comprise pharmacological agents, surgery, and combinations thereof. The device can be used to determine whether the intervention is inducing an irregular heartbeat by comparing readings taken before and after administration of the intervention, or during the course of therapy. Non-limiting examples of interventions used by a subject that can be monitored by the present invention include doxorubicin, adriamycin, capecitabine, gemcitabine, cytarabine, paclitaxel, docetaxel, cisplatin, carboplatin, oxaliplatin, 5-fluorouracil, chlorambucil, cyclophosphamide, busulfan, melphalan, arsenic trioxide, IL-2, methotrexate, trastuzumab, sunitinib, cetuximab, alemtuzumab, rituximab, thalidomide, amsacrine, dispeptide, and combinations thereof.
- The device described herein can be used to monitor cardiac activity in a subject using recreational drugs. The device can be used to determine whether the recreational drug use is inducing an irregular heartbeat by comparing readings taken in the presence and absence of recreational drug use, or during the course of recreational drug use. Non-limiting examples of recreational drugs used by a subject that can be monitored by the present invention include dextroamphetamine, methamphetamine, methylphenidate, fenfluramine, dexfenfluramine, MDMA, cocaine, phencyclidine, lysergic acid diethylamide, psilocybin, morphine, heroin, volatile inhalants, cannabis and combinations thereof.
- A detection system of the invention can comprise a transmitter, a receiver, and an antenna. The transmitter can generate a signal that is radiated into a space containing an object of interest by the antenna. The signal can then be reflected off the object of interest, and a reflected signal can be detected by the receiver. The receiver can amplify the signal for conversion to, for example, visual or audio data.
- Ultrasound involves the use of high frequency sound waves outside the range of human hearing to create images of, for example, organs and systems within the human body. Medical sonography is the practice of imaging organs within the body. Ultrasound images (sonograms) are made by sending a pulse of ultrasound into tissue using an ultrasound transducer. The sound reflects and echoes off parts of the tissue and this echo is recorded and displayed as an image to the operator.
- The electromagnetic (EM) spectrum is a continuum of all the possible frequencies of electromagnetic radiation. Electromagnetic radiation can be described by physical properties including frequency, wavelength, and energy. The different regions of the EM spectrum, in decreasing order of wavelength and increasing order of frequency, include radio waves, microwaves, far infrared, near infrared, visible, ultraviolet, X-rays, gamma rays, and high-energy gamma rays.
- Radio waves are generally propagated via the use of an antenna and can have wavelengths that range from hundreds of kilometers to a millimeter. Radio waves can be used for communication satellites, navigation systems, radio communication, broadcasting, and radar.
- Microwaves have wavelengths that range from one meter to millimeters. Microwaves are used in spacecraft communication and radar technology. Some television and telephone communications are transmitted long distances by microwaves between ground stations and communications satellites. Microwaves can be absorbed by molecules that have dipole moments in liquids.
- Infrared radiation is characterized by wavelengths that range from about a millimeter to several hundred nanometers. Infrared energy is emitted or absorbed by molecules when changing rotational-vibrational movements. Infrared energy elicits vibrational modes in a molecule through a change in the dipole moment, making infrared a useful frequency range for study of these energy states for molecules. Most thermal energy emitted from objects at room temperature is infrared.
- The visible region of the EM spectrum is the portion of the spectrum to which the human eye is most sensitive. Electromagnetic radiation with wavelengths of between 380 and 760 nanometers is detectable by the human eye and perceived as visible light.
- Ultraviolet (UV) radiation typically has wavelengths between 100 and 400 nanometers. UV light can be found in sunlight and has the potential to damage biological molecules due to its ability to alter chemical bonds. UV rays having very short wavelengths can ionize molecules.
- X-rays have wavelengths in the range of about one to tenths of a nanometer. X-rays have the ability to penetrate through relatively thick objects without much scattering or absorption, thus making them useful for imaging visually opaque objects and are widely used in medical radiography and airport security scanners.
- Gamma rays have extremely short wavelengths and a very high frequency. Natural sources of gamma rays include decay from naturally occurring radioisotopes. Gamma rays are also found in space as a result of supernova explosions. Due to their high energy, gamma rays are highly penetrating and can diffuse throughout the human body and cause radiation sickness.
- Radar (radio detection and ranging) is a system that can use radio waves or microwaves to determine the range, altitude, speed, and direction of objects. Radio waves are a portion of the electromagnetic spectrum and are characterized by low frequency and long wavelengths. A radar system can use radio waves as a mechanism for the detection of objects.
- Ultra-wideband (UWB) radar systems can use radio waves to transmit information spread over large bandwidths, for example, greater than 500 MHz. UWB radar systems can accomplish this task via pulse-modulation of the signal, in that UWB transmissions transmit information by generating radio waves at specific time intervals over a large bandwidth. Non-UWB transmissions can employ continuous signaling in which only the frequency, power level, or phase of the wave, but not the time interval, is changed.
- Doppler radar utilizes the Doppler effect to produce velocity data about objects at a distance. Doppler radar can beam a microwave signal toward a desired target and listen for a reflection. This process allows for analysis of how the object's motion alters the frequency of the returned signal motion, and provides data about the object's velocity.
- Continuous wave Doppler radar transmits a continuous wave of radio energy, allowing for the determination of an object's velocity without providing any range or distance data. Frequency-modulated continuous wave (FMCW) Doppler radar differs from continuous wave Doppler radar in that the frequency of the transmitted signal can be varied, allowing for measurements of an object's distance. Use of pseudorandom code modulated continuous wave radar can provide further refinement as to an object's distance and range. This refinement occurs via modulation of the transmitter's codes to meet frequency and range requirements for the objects of interest.
- Pulsed Doppler radar uses pulse-timing techniques and the Doppler effect to determine the distance of an object. Pulsed Doppler systems differ from continuous wave systems by sending short pulses of radio energy rather than a continuous transmission of radio energy to an object. The range of an object is determined by the measuring the elapsed time between pulses sent to and reflected off the object.
-
FIG. 5 depicts an example device of the present invention. Thedevice 502 can comprise anantenna 503 and be positioned in proximity to, for example, ahuman heart 501. The antenna can transmit 506 asignal 504 to the heart. Thesignal 504 can reflect off, for example, the muscle tissue of the heart. The reflectedsignal 505 can then be received 507 by thedevice 502 and processed for analysis. - Performance can be optimized by positioning a device on a subject for minimal signal loss in tissue.
FIG. 6 illustrates the tissue thickness, in inches, of skin, fat, muscle, and bone anterior to the heart of a human. The amount of muscle tissue is relatively low. When radar signals were radiated through various tissues including skin, fat, muscle, and bone, the greatest loss of radar signal occurred in the muscle tissue, as demonstrated inFIG. 7 . - The loss of signal intensity was correlated positively with the frequency of the signal, as shown in
FIG. 7 . When the frequency (GHz) of the signal was increased, the total loss of signal (dB) was most significant in the muscle, while other tissues only accounted for a minor portion of signal loss. This analysis further indicated that the sternum, having minimal musculature, should be an effective placement for the device. This placement allows for less signal loss and dispersion. - To calculate the interaction of transmitted signals generated by a device described herein with heart muscles, a three-dimensional full-wave simulation was employed. In this simulation, a three-dimensional model of the heart, or chest cavity, was used. First, the complexity of the model was reduced by removing portions of the chest cavity that do not move, and thus are not relevant for modeling the motion of the heart. Next, the heart model was imported into a wave simulation program to determine the signal received at the antenna in the form of a magnetic or electric field distribution. Finally, the extracted waveforms were fed into a circuit simulator to determine the correlation between the output signal and the motion of the heart.
- Various computer architectures are suitable for use with the invention.
FIG. 8 is a block diagram illustrating a first example architecture of acomputer system 800 that can be used in connection with example embodiments of the present invention. As depicted inFIG. 8 , the example computer system can include aprocessor 802 for processing instructions. Non-limiting examples of processors include: Intel Core i7™ processor, Intel Core i5™ processor, Intel Core i3™ processor, Intel Xeon™ processor, AMD Opteron™ processor, Samsung 32-bit RISC ARM 1176JZ(F)-S v1.0™ processor, ARM Cortex-A8 Samsung S5PC100™ processor, ARM Cortex-A8 Apple A4™ processor, Marvell PXA 930™ processor, or a functionally-equivalent processor. Multiple threads of execution can be used for parallel processing. In some embodiments, multiple processors or processors with multiple cores can be used, whether in a single computer system, in a cluster, or distributed across systems over a network comprising a plurality of computers, cell phones, tablet computing devices, watch based devices, wrist band devices, armband devices, or personal data assistant devices. - As illustrated in
FIG. 8 , ahigh speed cache 801 can be connected to, or incorporated in, theprocessor 802 to provide a high speed memory for instructions or data that have been recently, or are frequently, used byprocessor 802. Theprocessor 802 is connected to anorth bridge 806 by a processor bus 805. Thenorth bridge 806 is connected to random access memory (RAM) 803 by amemory bus 804 and manages access to theRAM 803 by theprocessor 802. Thenorth bridge 806 is also connected to asouth bridge 808 by a chipset bus 807. Thesouth bridge 808 is, in turn, connected to a peripheral bus 809. The peripheral bus can be, for example, PCI, PCI-X, PCI Express, or other peripheral bus. The north bridge and south bridge are often referred to as a processor chipset and manage data transfer between the processor, RAM, and peripheral components on the peripheral bus 809. In some architectures, the functionality of the north bridge can be incorporated into the processor instead of using a separate north bridge chip. - In some embodiments,
system 800 can include anaccelerator card 812 attached to the peripheral bus 809. The accelerator can include field programmable gate arrays (FPGAs) or other hardware for accelerating certain processing. - Software and data are stored in
external storage 813 and can be loaded intoRAM 803 and/orcache 801 for use by the processor. Thesystem 800 includes an operating system for managing system resources; non-limiting examples of operating systems include: Linux, Windows™, MACOS™, BlackBerry OS™, iOS™, Android™ and other functionally-equivalent operating systems, as well as application software running on top of the operating system. - In this example,
system 800 also includes network interface cards (NICs) 810 and 811 connected to the peripheral bus for providing network interfaces to external storage, such as Network Attached Storage (NAS) and other computer systems that can be used for distributed parallel processing. -
FIG. 9 is a diagram showing anetwork 900 with a plurality ofcomputer systems personal data assistants 902 c, and Network Attached Storage (NAS) 901 a, and 901 b. In some embodiments,systems computer systems assistant systems 902 c.Computer systems assistant systems 902 c can also provide parallel processing for adaptive data restructuring of the data stored in Network Attached Storage (NAS) 901 a and 901 b.FIG. 9 illustrates an example only, and a wide variety of other computer architectures and systems can be used in conjunction with the various embodiments of the present invention. For example, a blade server can be used to provide parallel processing. Processor blades can be connected through a back plane to provide parallel processing. Storage can also be connected to the back plane or as Network Attached Storage (NAS) through a separate network interface. - In some embodiments, processors can maintain separate memory spaces and transmit data through network interfaces, back plane, or other connectors for parallel processing by other processors. In some embodiments, some or all of the processors can use a shared virtual address memory space.
-
FIG. 10 is a block diagram of a multiprocessor computer system using a shared virtual address memory space. The system includes a plurality ofprocessors 1001 a-f that can access a sharedmemory subsystem 1002. The system incorporates a plurality of programmable hardware memory algorithm processors (MAPs) 1003 a-f in thememory subsystem 1002. Each MAP 1003 a-f can comprise a memory 1004 a-f and one or more field programmable gate arrays (FPGAs) 1005 a-f. The MAP provides a configurable functional unit and particular algorithms or portions of algorithms can be provided to the FPGAs 1005 a-f for processing in close coordination with a respective processor. In this example, each MAP is globally accessible by all of the processors for these purposes. In one configuration, each MAP can use Direct Memory Access (DMA) to access an associated memory 1004 a-f, allowing it to execute tasks independently of, and asynchronously from, therespective microprocessor 1001 a-f. In this configuration, a MAP can feed results directly to another MAP for pipelining and parallel execution of algorithms. - The above computer architectures and systems are examples only, and a wide variety of other computer, cell phone, and personal data assistant architectures and systems can be used in connection with example embodiments, including systems using any combination of general processors, co-processors, FPGAs and other programmable logic devices, system on chips (SOCs), application specific integrated circuits (ASICs), and other processing and logic elements. Any variety of data storage media can be used in connection with example embodiments, including random access memory, hard drives, flash memory, tape drives, disk arrays, Network Attached Storage (NAS) and other local or distributed data storage devices and systems.
- In example embodiments, the computer system can be implemented using software modules executing on any of the above or other computer architectures and systems. In other embodiments, the functions of the system can be implemented partially or completely in firmware, programmable logic devices such as field programmable gate arrays (FPGAs) as referenced in
FIG. 10 , system on chips (SOCs), application specific integrated circuits (ASICs), or other processing and logic elements. For example, the Set Processor and Optimizer can be implemented with hardware acceleration through the use of a hardware accelerator card, such asaccelerator card 812 illustrated inFIG. 8 . - Any embodiment of the invention described herein can be, for example, produced and transmitted by a user within the same geographical location. A product of the invention can be, for example, produced and/or transmitted from a geographic location in one country and a user of the invention can be present in a different country. In some embodiments, the data accessed by a system of the invention is a computer program product that can be transmitted from one of a plurality of
geographic locations 1101 to a user 1102 (FIG. 11 ). Data generated by a computer program product of the invention can be transmitted back and forth among a plurality of geographic locations, for example, by a network, a secure network, an insecure network, an internet, or an intranet. In some embodiments, an ontological hierarchy provided by the invention is encoded on a physical and tangible product. - Any embodiment of the invention described herein can be produced and/or transmitted in an encoded form, for example, a radio frequency identification tag or barcode. In some embodiments, the data accessed by a system of the invention can be accessed from the encoded form either directly or as part of a health record. In some embodiments, the health record can be an electronic health record or digital health record. In some embodiments, the health record can be accessed by the subject or a health care provider for the subject.
- One embodiment of the invention described herein is shown in
FIG. 14 , panel A. A human subject stands or sits in a way that they can avoid shaking their body. The subject holds a radar device attached to their body using either their hand or a chest strap. An ECG is simultaneously recorded by a three-electrode ECG circuit with three electrodes attached to a wrist and the left and right ankles. The device and ECG circuit is connected to a computer that performs the signal processing and waveform display. - As shown in
FIG. 14 , panel B, the device can be disposed in various positions on the subject's chest, resulting in differences in the efficacy and output. The device can also be put against the back of the human subject to record data. - The human subject is in a comfortable and warm environment and is relaxed. The subject can stand, sit, walk or lie down on a bed. The device can be positioned to contact the skin or can be placed outside the subject's clothing. In the clothed setting, the device can be placed tightly against chest of the subject.
- Three subjects were monitored using a device of the invention. All data were taken with the subjects in a held breath state.
FIG. 15 , panel A shows the ECG signal on the top graph and the radar signal on the bottom graph detected in a healthy young man.FIG. 15 , panel B shows the ECG signal on the top graph and the radar signal on the bottom graph detected in a healthy elderly man.FIG. 15 , panel C shows the ECG signal on the top graph and the radar signal on the bottom graph detected in an elderly man with an irregular heartbeat, who is in atrial fibrillation. In panels A and B, the small first pulse was generated by the motion of the atrium and the larger second pulse was generated by the motion of the ventricles. In panels A and B, the radar signals from the invention correlated with the ECG signals and were in the same periodicity as the ECG signals. In panel C, the radar signal correlated with the ECG signal but showed little evidence of atrial motion. -
FIG. 16 shows the ECG signal on the top graph and the radar signal on the bottom graph detected in the healthy young man in Example 5 while breathing. The additional low frequency signal superimposed on the radar heart motion signal represents the motion of the chest cavity as a result of breathing. - As described in Example 4,
FIG. 17 shows the ECG signal on the top graph and the radar signal on the bottom graph when a representative device of the invention was positioned at different locations on the chest of the healthy young man from Example 5. Panel A illustrates the ECG and radar signals measured at the center of the chest. Panel B illustrates the ECG and radar signals measured above the center of the chest Panel C illustrates the ECG and radar signals measured below the center of the chest. Panel D illustrates the ECG and radar signals measured left of the center of the chest. Panel E illustrates the ECG and radar signals measured right of the center of the chest. These graphs show that positioning the device at various locations on the chest allowed views of different portions of the heart. Viewing different portions of the heart can assist evaluation of various heart abnormalities. -
FIG. 18 shows the ECG signal on the top graph and the radar signal on the bottom graph obtained when a device of the invention was positioned on the back of the healthy young man from Example 5. These data represent measurements of atrial motion by positioning the device on the back of the subject. -
FIG. 21 shows three measurements taken from a healthy male subject at different distances. All of these data were taken with the subject in a held breath state. These data represent measurements of atrial motion by positioning an embodiment of the invention at a distance from the subject. -
FIG. 19 , panel A illustrates an embodiment of a device to determine the motion of the heart of a subject. Theradar system 1901 connected to anantenna 1902 propagates a transmittedwaveform 1903 towards atarget 1904, for example, a heart of a subject. A reflectedwaveform 1905 is then received by theantenna 1902. The distance between theantenna 1902 and thetarget 1904 is defined by the function 1906 d-x(t), where d is a constant distance between theantenna 1902 and thetarget 1904 and x(t) is the motion function of thetarget 1904, for example, the original motion of the heart of the subject. Panels B-D represent measured waveforms at three different distances between theantenna 1902 andtarget 1904. - The
radar system 1901 transmits a cosine signal written as -
T(t)=A·cos(2 πft); - where A is the amplitude of the transmitted
waveform 1903, f is the frequency of transmittedwaveform 1903, and t is time. - The reflected signal is written as
-
- where B is the amplitude of the reflected
waveform 1905 and lambda is the wavelength of reflectedwaveform 1905. - After demodulation, two output signals can exist. One is called an in-phase signal (I) and the other is called a quadrature signal (Q). The in-phase signal is written as
-
- and the quadrature signal is written as
-
- where C is the amplitude of the signal.
- By dividing Q(t) by I(t), the signal ratio Y is obtained, which is written as
-
- Thus, solution is possible for the motion function of the target in terms of the signal ratio, with x(t) written as
-
- Quadrature demodulation as described herein can allow for precise calculation of the motion function of the
target 1904, since motion of thetarget 1904 is quite small compared with the wavelength of the reflectedwaveform 1905. -
FIG. 20 illustrates an embodiment of the method of continuous monitoring described in the invention. For example, a subject can wear a device continuously for long-term monitoring 2001 to determine the percentage of cardiacarrhythmic time 2002. These data are recorded and stored over long periods of time, for example, hours, days, weeks, or months. Signal recognition software detects and highlights important events for review by a health care provider. The health care provider uses the percentage of cardiacarrhythmic time 2002 to determine the appropriatemedical intervention 2003. Non-limiting examples of medical interventions include continued monitoring; cardioversion with or without specific pharmaceuticals; cardiac ablation with or without specific pharmaceuticals; and cardiac ablation with or without introduction of a pacemaker. - The following non-limiting embodiments provide illustrative examples of the invention, but do not limit the scope of the invention.
-
Embodiment 1. A method of detecting an irregular heartbeat in a subject, the method comprising: a) transmitting a wavelength of electromagnetic radiation to the heart of the subject; b) detecting an electromagnetic signal reflected off the heart of the subject; and c) determining based on the electromagnetic signal reflected off the heart of the subject whether the subject has an irregular heartbeat. -
Embodiment 2. The method ofEmbodiment 1, wherein the subject is undergoing an intervention for the irregular heartbeat, the method further comprising determining based on the electromagnetic signal reflected off the heart of the subject whether the intervention for the irregular heartbeat has modulated the irregular heartbeat. -
Embodiment 3. The method ofEmbodiment 1, wherein the subject is undergoing an intervention for a non-irregular heartbeat condition, the method further comprising determining based on the electromagnetic signal reflected off the heart of the subject whether the intervention for the non-irregular heartbeat condition has induced the irregular heartbeat. -
Embodiment 4. The method of any one of Embodiments 1-3, wherein the determination whether the subject has an irregular heartbeat is determined by an analysis of a movement of a portion of the heart. -
Embodiment 5. The method of any one of Embodiments 1-4, further comprising attaching a source of electromagnetic radiation to the subject's body. -
Embodiment 6. The method ofEmbodiment 5, wherein the source of electromagnetic radiation is attached to the subject's body in proximity to the subject's heart. -
Embodiment 7. The method ofEmbodiment 5, wherein the source of electromagnetic radiation is attached to the subject's chest. -
Embodiment 8. The method ofEmbodiment 5, wherein the source of electromagnetic radiation is attached to the subject's back. -
Embodiment 9. The method of any one of Embodiments 1-8, wherein the subject is in a held-breath state. -
Embodiment 10. The method of any one of Embodiments 1-9, wherein the wavelength of electromagnetic radiation transmitted to the heart of the subject is a radio wave. - Embodiment 11. The method of any one of Embodiments 1-10, wherein the irregular heartbeat is associated with atrial fibrillation.
- Embodiment 12. The method of any one of Embodiments 1-10, wherein the irregular heartbeat is associated with atrial flutter.
- Embodiment 13. The method of any one of Embodiments 1-10, wherein the irregular heartbeat is associated with ventricular fibrillation.
- Embodiment 14. The method of any one of Embodiments 1-10, wherein the irregular heartbeat is associated with ventricular flutter.
- Embodiment 15. The method of any one of Embodiments 1-10, wherein the irregular heartbeat is associated with cardiac arrhythmia.
-
Embodiment 16. The method of any one of Embodiments 1-15, wherein the subject is human. - Embodiment 17. A method comprising: a) receiving by a computer system data associated with an electromagnetic signal reflected off a heart of a subject; b) comparing by a processor of the computer system the data associated with the electromagnetic signal reflected off the heart of the subject to a reference; c) determining based on the comparison of the data associated with the electromagnetic signal reflected off the heart of the subject to the reference whether the subject has an irregular heartbeat; and d) outputting a result of the determination.
- Embodiment 18. The method of Embodiment 17, wherein the subject is undergoing an intervention for the irregular heartbeat, the method further comprising determining based on the electromagnetic signal reflected off the heart of the subject whether the intervention for the irregular heartbeat has modulated the irregular heartbeat.
- Embodiment 19. The method of Embodiment 17, wherein the subject is undergoing an intervention for a non-irregular heartbeat condition, the method further comprising determining based on the electromagnetic signal reflected off the heart of the subject whether the intervention for the non-irregular heartbeat condition has induced the irregular heartbeat.
-
Embodiment 20. The method of any one of Embodiments 17-19, wherein the determination that the subject has an irregular heartbeat is determined by an analysis of a movement of a portion of the heart. - Embodiment 21. The method of any one of Embodiments 17-20, wherein the irregular heartbeat is associated with atrial fibrillation.
- Embodiment 22. The method of any one of Embodiments 17-20, wherein the irregular heartbeat is associated with atrial flutter.
- Embodiment 23. The method of any one of Embodiments 17-20, wherein the irregular heartbeat is associated with ventricular fibrillation.
- Embodiment 24. The method of any one of Embodiments 17-20, wherein the irregular heartbeat is associated with ventricular flutter.
- Embodiment 25. The method of any one of Embodiments 17-20, wherein the irregular heartbeat is associated with cardiac arrhythmia.
- Embodiment 26. The method of any one of Embodiments 17-25, wherein the subject is human.
- Embodiment 27. A device comprising: a) an antenna configured to transmit electromagnetic radiation into a thoracic cavity of a subject; b) a receiver configured to detect an electromagnetic signal reflected off the subject's heart; and c) a processor configured to identify an irregular heartbeat in the subject based on the detected electromagnetic signal reflected off the subject's heart.
- Embodiment 28. The device of Embodiment 27, wherein the antenna configured to transmit the electromagnetic radiation into the thoracic cavity of the subject, the receiver configured to detect the electromagnetic signal reflected off the subject's heart, and the processor configured to identify the irregular heartbeat in the subject based on the detected electromagnetic signal reflected off the subject's heart, are contained in a common housing.
- Embodiment 29. The device of any one of Embodiments 27-28, further comprising a circuit configured to generate a signal suitable for transmission into the thoracic cavity of the subject by the antenna.
-
Embodiment 30. The device of any one of Embodiments 27-29, wherein the processor is configured to detect the irregular heartbeat in a subject by measuring time intervals among signals received after reflection off the subject's heart. - Embodiment 31. The device of any one of Embodiments 27-30, wherein the antenna is configured to transmit electromagnetic radiation that is a radio wave.
- Embodiment 32. The device of any one of Embodiments 27-31, wherein the device is configured to be attached to the subject in proximity to the subject's heart.
- Embodiment 33. The device of any one of Embodiments 27-32, wherein the device is configured to be attached to the subject on the subject's chest.
- Embodiment 34. The device of any one of Embodiments 27-32, wherein the device is configured to be attached to the subject on the subject's back.
- Embodiment 35. The device of any one of Embodiments 24-34, wherein the processor is configured to identify an irregular heartbeat associated with atrial fibrillation.
- Embodiment 36. The device of any one of Embodiments 24-34, wherein the processor is configured to identify an irregular heartbeat associated with atrial flutter.
- Embodiment 37. The device of any one of Embodiments 24-34, wherein the processor is configured to identify an irregular heartbeat associated with ventricular fibrillation.
- Embodiment 38. The device of any one of Embodiments 24-34, wherein the processor is configured to identify an irregular heartbeat associated with ventricular flutter.
- Embodiment 39. The device of any one of Embodiments 24-34, wherein the processor is configured to identify an irregular heartbeat associated with cardiac arrhythmia.
-
Embodiment 40. A device comprising: a) an antenna configured to transmit electromagnetic radiation into a thoracic cavity of a subject; b) a receiver configured to detect an electromagnetic signal reflected off the subject's heart; and c) a transmitter configured to transmit data associated with the received electromagnetic signal reflected off the subject's heart. - Embodiment 41. The device of
Embodiment 40, wherein the antenna configured to transmit the electromagnetic radiation into the thoracic cavity of the subject, the receiver configured to detect the electromagnetic signal reflected off the subject's heart, and the transmitter configured to transmit data associated with the received electromagnetic signal reflected off the subject's heart, are contained in a common housing. - Embodiment 42. The device of any one of Embodiments 40-41, further comprising a circuit configured to generate a signal suitable for transmission into the thoracic cavity of the subject by the antenna.
- Embodiment 43. The device of any one of Embodiments 40-42, wherein the transmitter is configured to transmit wirelessly to a remote processor.
- Embodiment 44. The device of any one of Embodiments 40-43, wherein the antenna is configured to transmit electromagnetic radiation that is a radio wave.
- Embodiment 45. The device of any one of Embodiments 40-44, wherein the device is configured to be attached to the subject in proximity to the subject's heart.
- Embodiment 46. The device of any one of Embodiments 40-45, wherein the device is configured to be attached to the subject on the subject's chest.
- Embodiment 47. The device of any one of Embodiments 40-45, wherein the device is configured to be attached to the subject on the subject's back.
- Embodiment 48. A method comprising: a) administering to a subject having an irregular heartbeat an intervention for the irregular heartbeat; b) monitoring the subject with a radar device; and c) determining based on the monitoring whether the intervention for the irregular heartbeat modulates the irregular heartbeat in the subject.
- Embodiment 49. The method of Embodiment 48, wherein the radar device monitors a movement of a portion of the subject's heart.
- Embodiment 50. The method of any one of Embodiments 48-49, wherein the processor is configured to identify an irregular heartbeat associated with atrial fibrillation.
- Embodiment 51. The method of any one of Embodiments 48-49, wherein the processor is configured to identify an irregular heartbeat associated with atrial flutter.
- Embodiment 52. The method of any one of Embodiments 48-49, wherein the processor is configured to identify an irregular heartbeat associated with ventricular fibrillation.
- Embodiment 53. The method of any one of Embodiments 48-49, wherein the processor is configured to identify an irregular heartbeat associated with ventricular flutter.
- Embodiment 54. The method of any one of Embodiments 48-49, wherein the processor is configured to identify an irregular heartbeat associated with cardiac arrhythmia.
- Embodiment 55. A method comprising: a) administering to a subject an intervention; b) monitoring the subject with a radar device; and c) determining based on the monitoring whether the intervention induces an irregular heartbeat in the subject.
- Embodiment 56. The method of Embodiment 55, wherein the radar device monitors a movement of a portion of the subject's heart.
- Embodiment 57. The method of any one of Embodiments 55-56, wherein the processor is configured to identify an irregular heartbeat associated with atrial fibrillation.
- Embodiment 58. The method of any one of Embodiments 55-56, wherein the processor is configured to identify an irregular heartbeat associated with atrial flutter.
- Embodiment 59. The method of any one of Embodiments 55-56, wherein the processor is configured to identify an irregular heartbeat associated with ventricular fibrillation.
-
Embodiment 60. The method of any one of Embodiments 55-56, wherein the processor is configured to identify an irregular heartbeat associated with ventricular flutter. - Embodiment 61. The method of any one of Embodiments 55-56, wherein the processor is configured to identify an irregular heartbeat associated with cardiac arrhythmia.
- Embodiment 62. The method of any one of Embodiments 55-61, wherein the subject has a non-irregular heartbeat condition, and the intervention is for the non-irregular heartbeat condition.
- Embodiment 63. A method comprising: a) transmitting a wavelength of electromagnetic radiation to the heart of the subject; b) detecting an electromagnetic signal reflected off the heart of the subject; and c) determining based on the electromagnetic signal reflected off the heart of the subject a change in volume of the heart of the subject.
- Embodiment 64. The method of Embodiment 63, further comprising determining a volume of blood output from the heart of the subject based on the change in volume of the heart of the subject.
- Embodiment 65. The method of any one of Embodiments 63-64, wherein the change in volume of the heart of the subject is determined within a single chamber of the heart of the subject.
Claims (27)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/399,140 US20220031187A1 (en) | 2014-06-11 | 2021-08-11 | Portable Heart Motion Monitor |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462010653P | 2014-06-11 | 2014-06-11 | |
US201562145649P | 2015-04-10 | 2015-04-10 | |
US14/736,745 US11116416B2 (en) | 2014-06-11 | 2015-06-11 | Portable heart motion monitor |
US17/399,140 US20220031187A1 (en) | 2014-06-11 | 2021-08-11 | Portable Heart Motion Monitor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/736,745 Continuation US11116416B2 (en) | 2014-06-11 | 2015-06-11 | Portable heart motion monitor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220031187A1 true US20220031187A1 (en) | 2022-02-03 |
Family
ID=54834344
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/736,745 Active US11116416B2 (en) | 2014-06-11 | 2015-06-11 | Portable heart motion monitor |
US17/399,140 Pending US20220031187A1 (en) | 2014-06-11 | 2021-08-11 | Portable Heart Motion Monitor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/736,745 Active US11116416B2 (en) | 2014-06-11 | 2015-06-11 | Portable heart motion monitor |
Country Status (7)
Country | Link |
---|---|
US (2) | US11116416B2 (en) |
EP (1) | EP3154423A4 (en) |
JP (1) | JP6665171B6 (en) |
CN (1) | CN106793967A (en) |
AU (1) | AU2015274528B2 (en) |
CA (1) | CA2951722A1 (en) |
WO (1) | WO2015191905A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9924880B2 (en) * | 2015-02-11 | 2018-03-27 | Samsung Electronics Co., Ltd. | RF doppler bio-signal sensor for continuous heart rate variability and blood pressure monitoring |
WO2017210440A1 (en) * | 2016-06-01 | 2017-12-07 | The Trustees Of Columbia University In The City Of New York | Methods and systems for ultrasound elastography |
EP3437554A1 (en) * | 2017-08-02 | 2019-02-06 | Koninklijke Philips N.V. | Device and method for detecting atrial fibrillation of a subject |
JP6873022B2 (en) * | 2017-10-12 | 2021-05-19 | オムロン株式会社 | Biometric information measuring device, blood pressure measuring device, device, biometric information measuring method, and blood pressure measuring method |
EP3764885A4 (en) * | 2018-03-15 | 2022-03-16 | Blumio, Inc. | System and method for cardiovascular health monitoring |
US11647978B2 (en) * | 2019-11-25 | 2023-05-16 | The Regents Of The University Of California | Pulmonary artery pressure change monitor |
GB2615427B (en) * | 2023-04-06 | 2024-07-03 | Gloucester Hospitals Nhs Found Trust | Scanning system and method |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5511553A (en) | 1989-02-15 | 1996-04-30 | Segalowitz; Jacob | Device-system and method for monitoring multiple physiological parameters (MMPP) continuously and simultaneously |
US5292348A (en) | 1991-06-14 | 1994-03-08 | Telectronics Pacing Systems, Inc. | Implantable cardioverter/defibrillator and method employing cross-phase spectrum analysis for arrhythmia detection |
US5274271A (en) | 1991-07-12 | 1993-12-28 | Regents Of The University Of California | Ultra-short pulse generator |
US5738102A (en) | 1994-03-31 | 1998-04-14 | Lemelson; Jerome H. | Patient monitoring system |
US5573012A (en) * | 1994-08-09 | 1996-11-12 | The Regents Of The University Of California | Body monitoring and imaging apparatus and method |
US6470210B1 (en) * | 2001-04-06 | 2002-10-22 | Cardiac Pacemakers, Inc. | System and method for continuously monitoring classified atrial arrhythmias |
US8892189B2 (en) | 2002-05-30 | 2014-11-18 | Alcatel Lucent | Apparatus and method for heart size measurement using microwave doppler radar |
DE10259522A1 (en) * | 2002-12-19 | 2004-07-01 | Robert Bosch Gmbh | Radar-based sensing of the position and / or movement of the body or in the body of living beings |
US6681404B1 (en) * | 2003-03-25 | 2004-01-27 | Terry K. Adlard | Garment with pouch for medical monitor |
US20040249257A1 (en) | 2003-06-04 | 2004-12-09 | Tupin Joe Paul | Article of manufacture for extracting physiological data using ultra-wideband radar and improved signal processing techniques |
KR20050010549A (en) | 2003-07-21 | 2005-01-28 | 엘지전자 주식회사 | minimum size antenna for UWB communication |
JP2005084141A (en) | 2003-09-04 | 2005-03-31 | Ricoh Co Ltd | Image forming apparatus and control method therefor |
US20070118054A1 (en) | 2005-11-01 | 2007-05-24 | Earlysense Ltd. | Methods and systems for monitoring patients for clinical episodes |
US20060094937A1 (en) | 2004-11-03 | 2006-05-04 | Marcott International Investment, Co. Ltd. | Monitoring apparatus of arterial pulses and method for the same |
US20090048500A1 (en) | 2005-04-20 | 2009-02-19 | Respimetrix, Inc. | Method for using a non-invasive cardiac and respiratory monitoring system |
CN101262814B (en) * | 2005-07-15 | 2010-12-08 | 皇家飞利浦电子股份有限公司 | Apparatus for defibrillation pulse detection using electromagnetic waves |
WO2007063516A2 (en) * | 2005-11-30 | 2007-06-07 | Philips Intellectual Property & Standards Gmbh | Radar system for remotely measuring a subject' s heartrate |
US8502729B2 (en) | 2006-01-30 | 2013-08-06 | Lawrence Livermore National Security, Llc | Ultra-wideband radar sensors and networks |
CN101437442B (en) | 2006-03-06 | 2011-11-16 | 森赛奥泰克公司 | Ultra wideband monitoring systems and antennas |
US7916066B1 (en) | 2006-04-27 | 2011-03-29 | Josef Osterweil | Method and apparatus for a body position monitor and fall detector using radar |
US20080074307A1 (en) * | 2006-05-17 | 2008-03-27 | Olga Boric-Lubecke | Determining presence and/or physiological motion of one or more subjects within a doppler radar system |
US8562526B2 (en) | 2006-06-01 | 2013-10-22 | Resmed Sensor Technologies Limited | Apparatus, system, and method for monitoring physiological signs |
JP2010500075A (en) * | 2006-08-09 | 2010-01-07 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | System and method for positioning a sensor for obtaining a life parameter of a subject |
JP2010502257A (en) * | 2006-08-30 | 2010-01-28 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Device for monitoring pulsating objects in the body |
JP5628520B2 (en) | 2006-11-01 | 2014-11-19 | レスメッド センサー テクノロジーズ リミテッド | Cardiopulmonary parameter monitoring system |
US7884727B2 (en) | 2007-05-24 | 2011-02-08 | Bao Tran | Wireless occupancy and day-light sensing |
US8463361B2 (en) * | 2007-05-24 | 2013-06-11 | Lifewave, Inc. | System and method for non-invasive instantaneous and continuous measurement of cardiac chamber volume |
JP2010537766A (en) | 2007-09-05 | 2010-12-09 | センシブル メディカル イノヴェイションズ リミテッド | Method, system, and apparatus for using electromagnetic radiation to monitor a user's tissue |
US8548577B2 (en) * | 2007-10-02 | 2013-10-01 | Koninklijke Philips N.V. | Detection of electrical and mechanical cardio-vascular activities |
WO2009081331A1 (en) * | 2007-12-19 | 2009-07-02 | Koninklijke Philips Electronics N.V. | Apparatus, method and computer program for measuring properties of an object |
US20100152600A1 (en) * | 2008-04-03 | 2010-06-17 | Kai Sensors, Inc. | Non-contact physiologic motion sensors and methods for use |
US7753849B2 (en) | 2008-05-09 | 2010-07-13 | Alcatel-Lucent Usa Inc. | Doppler radar cardiopulmonary sensor and signal processing system and method for use therewith |
US8989837B2 (en) * | 2009-12-01 | 2015-03-24 | Kyma Medical Technologies Ltd. | Methods and systems for determining fluid content of tissue |
WO2010054409A1 (en) * | 2008-11-10 | 2010-05-14 | Cardioinsight Technologies, Inc. | Visualization of electrophysiology data |
CA2789521A1 (en) | 2009-02-25 | 2010-09-02 | Xanthia Global Limited | Wireless physiology monitor |
US20100274145A1 (en) * | 2009-04-22 | 2010-10-28 | Tupin Jr Joe Paul | Fetal monitoring device and methods |
US8378879B2 (en) | 2009-06-18 | 2013-02-19 | The Johns Hopkins University | Apparatus and methods for remote detection of physiological changes |
US8903490B2 (en) * | 2010-03-03 | 2014-12-02 | Cardiac Pacemakers, Inc. | Methods and systems for recognizing arrhythmias using neural stimulation |
EP2368492A1 (en) | 2010-03-25 | 2011-09-28 | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO | A method for estimating parameters indicative of a heart performance, a radar system and a computer program product |
WO2011117724A2 (en) | 2010-03-26 | 2011-09-29 | Raviv Melamed | Apparatus and method for doppler-assisted mimo radar microwave imaging |
EP2571418A4 (en) | 2010-05-20 | 2013-10-30 | Lifeflow Technologies Inc | Patient monitoring and surveillance system, methods, and devices |
EP2417908A1 (en) * | 2010-08-12 | 2012-02-15 | Philips Intellectual Property & Standards GmbH | Device, system and method for measuring vital signs |
EP2517621A1 (en) | 2011-04-29 | 2012-10-31 | Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO | A radar apparatus for detecting multiple life-signs of a subject, a method and a computer program product |
US8740793B2 (en) * | 2011-08-29 | 2014-06-03 | General Electric Company | Radar based systems and methods for monitoring a subject |
US9713434B2 (en) | 2012-02-11 | 2017-07-25 | Sensifree Ltd. | Microwave contactless heart rate sensor |
US8903480B2 (en) * | 2012-04-11 | 2014-12-02 | Siemens Medical Solutions Usa, Inc. | System for cardiac condition detection using heart waveform area associated analysis |
LT2840962T (en) * | 2012-04-23 | 2024-07-10 | Precordior Oy | Apparatus and computer program for producing a signal expressing atrial fibrillation |
CN202669497U (en) | 2012-05-29 | 2013-01-16 | 浙江吉利汽车研究院有限公司杭州分公司 | Vehicle-mounted heart monitoring safety driving device |
-
2015
- 2015-06-11 JP JP2017517214A patent/JP6665171B6/en active Active
- 2015-06-11 WO PCT/US2015/035405 patent/WO2015191905A1/en active Application Filing
- 2015-06-11 AU AU2015274528A patent/AU2015274528B2/en active Active
- 2015-06-11 CA CA2951722A patent/CA2951722A1/en active Pending
- 2015-06-11 EP EP15806524.3A patent/EP3154423A4/en active Pending
- 2015-06-11 US US14/736,745 patent/US11116416B2/en active Active
- 2015-06-11 CN CN201580042373.8A patent/CN106793967A/en active Pending
-
2021
- 2021-08-11 US US17/399,140 patent/US20220031187A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US11116416B2 (en) | 2021-09-14 |
JP6665171B6 (en) | 2020-04-08 |
AU2015274528B2 (en) | 2019-09-19 |
EP3154423A4 (en) | 2018-02-07 |
EP3154423A1 (en) | 2017-04-19 |
US20150359463A1 (en) | 2015-12-17 |
JP2017523011A (en) | 2017-08-17 |
CA2951722A1 (en) | 2015-12-17 |
JP6665171B2 (en) | 2020-03-13 |
AU2015274528A1 (en) | 2017-01-05 |
WO2015191905A1 (en) | 2015-12-17 |
CN106793967A (en) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220031187A1 (en) | Portable Heart Motion Monitor | |
Wang et al. | A novel ultra-wideband 80 GHz FMCW radar system for contactless monitoring of vital signs | |
JP6386327B2 (en) | Cardiopulmonary parameter monitoring apparatus and cardiopulmonary parameter monitoring system | |
Paulson et al. | Ultra-wideband radar methods and techniques of medical sensing and imaging | |
EP3181045B1 (en) | Methods and systems for monitoring intrabody tissues | |
US10667715B2 (en) | Methods and devices of cardiac tissue monitoring and analysis | |
Varma et al. | 2021 ISHNE/HRS/EHRA/APHRS expert collaborative statement on mHealth in arrhythmia management: digital medical tools for heart rhythm professionals: from the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society | |
US20080200802A1 (en) | Platform for detection of tissue content and/or structural changes with closed-loop control in mammalian organisms | |
CN107205667A (en) | The Noninvasive of the other functional states and trend of health of heart and Human Physiology system is determined | |
CN105377127A (en) | System and method for monitoring and diagnosing patient condition based on wireless sensor monitoring data | |
US11647978B2 (en) | Pulmonary artery pressure change monitor | |
JP2009501044A (en) | Device for detecting heart activity | |
CN102843959A (en) | Method of characterizing the pathological response of tissue to a treatmant plan | |
Churkin et al. | Millimeter-wave radar for vital signs monitoring | |
Li et al. | Remote respiratory and cardiac motion patterns separation with 4D imaging radars | |
Wu et al. | Non-intrusive human vital sign detection using mmwave sensing technologies: A review | |
Suzuki et al. | Remote sensing for medical and health care applications | |
KR102538647B1 (en) | Apparatus for Determining Rarity of Biometric data and Method thereof | |
Dong et al. | A Review on Recent Advancements of Biomedical Radar for Clinical Applications | |
Birsan et al. | Non-contact cardiopulmonary monitoring algorithm for a 24 GHz Doppler radar | |
Xue et al. | An ECG arrhythmia classification and heart rate variability analysis system based on android platform | |
US20230363654A1 (en) | Beamforming systems and methods for detecting heart beats | |
Baird | Human activity and posture classification using single non-contact radar sensor | |
Lu et al. | Doppler radar noncontact vital sign monitoring | |
Pan | Vital signs monitoring based on UWB radar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LIU, XIAOGUANG;BI, SONJIE;REEL/FRAME:057833/0136 Effective date: 20161010 Owner name: CARDIAC MOTION, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TIRHR, LLC;REEL/FRAME:057833/0131 Effective date: 20151006 Owner name: TIRHR, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MATTHEWS, DENNIS;REEL/FRAME:057833/0110 Effective date: 20151006 Owner name: CARDIAC MOTION, LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MATTHEWS, DENNIS;REEL/FRAME:057833/0098 Effective date: 20151006 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CARDIAC MOTION, LLC;REEL/FRAME:064416/0234 Effective date: 20230727 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |